1
|
Trivedi K, Anand S, Atta P, Kujur M, Kujur A, Singh S, Prasad A, Kiran KA. Drivers for COVID 19 vaccine hesitancy among breastfeeding women in Eastern tribal state, India. J Family Med Prim Care 2023; 12:3167-3171. [PMID: 38361909 PMCID: PMC10866274 DOI: 10.4103/jfmpc.jfmpc_821_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Revised: 06/29/2023] [Accepted: 07/04/2023] [Indexed: 02/17/2024] Open
Abstract
Background In the COVID-19 pandemic age, vaccination hesitancy also known as vaccine refusal is a cause for worry since it hinges on the five Cs of confidence, complacency, convenience, calculation, and shared responsibility. The current study was to pinpoint the elements that contribute to breastfeeding women's hesitation to receive the coronavirus disease-19 (COVID-19) vaccine. Materials and Methods A cross-sectional observational study was carried out at the Department of Obstetrics and Gynaecology, Tertiary Care Hospital, Ranchi, Jharkhand. Result Out of 365 nursing mothers, 242 (66.3%) were hesitant to get the COVID-19 vaccination. Those who chose not to receive the COVID-19 vaccination mostly belong to those aged 18 to 25 (38.1%), living in rural regions (44.9%), and belonging to non-tribal ethnic groups (41.1%). On application of logistic regression, it was found that rural areas had 3 times higher rate of vaccine hesitancy than urban residents, and that husbands' education levels up to the 12th grade had a 3.55 times higher rate and 5 times agriculture by husband's occupation, which was statistically significant (P value less than 0.05) The most prevalent grounds for rejection were fear of side effects (85.8%) and worry of adverse effects on newborns (83.48%). Conclusion Both husband and wife, who had completed high school and were aware of the vaccination, were fearful of the COVID-19 vaccine. Concerns about the side effects and undesirable effects of vaccination on their newborns were the main reasons for refusal.
Collapse
Affiliation(s)
- Kiran Trivedi
- Department of Obstetrics and Gynaecology, Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand, India
| | - Shikha Anand
- Department of Obstetrics and Gynaecology, Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand, India
| | - Prami Atta
- Department of Obstetrics and Gynaecology, Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand, India
| | - Manisha Kujur
- Department of Community Medicine, Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand, India
| | - Anit Kujur
- Department of Community Medicine, Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand, India
| | - Shashibala Singh
- Department of Obstetrics and Gynaecology, Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand, India
| | - Anupa Prasad
- Department of Biochemistry, Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand, India
| | - Kumari Asha Kiran
- Department of Community Medicine, Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand, India
| |
Collapse
|
2
|
Saraswat N, Tripathy DM, Murali M, Boruah J, Mitra D, Chopra H, Bhatnagar A. A Study to Describe the Pattern of Cutaneous Adverse Effects of COVID-19 Vaccines ( Covishield and Covaxin). Indian Dermatol Online J 2023; 14:814-820. [PMID: 38099027 PMCID: PMC10718090 DOI: 10.4103/idoj.idoj_539_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Revised: 03/26/2023] [Accepted: 04/16/2023] [Indexed: 12/17/2023] Open
Abstract
Background Vigorous administration of COVID-19 vaccines to tackle the ongoing pandemic has led to increasing research on adverse effects including both systemic and cutaneous. Objective A prospective observational study to delineate the cutaneous adverse effects of two vaccines, namely Covishield and Covaxin, administered in two doses in northern India. Materials and Methods The study was conducted in a tertiary hospital in northern India wherein patients were asked to report voluntarily any cutaneous adverse effects after COVID-19 vaccination to the dermatology department. The data were collected using excel sheets and later analyzed taking into consideration the age, vaccine types, and duration of onset of adverse effects. Results Of the 19,672 vaccination jabs, 296 (1.5%) developed cutaneous adverse effects of which the incidence was higher in Covishield vaccine group compared to Covaxin vaccine group. The incidence of side effects was more with the first dose of either vaccine compared to the second dose. All the side effects were benign and were managed symptomatically or were self-limiting. Limitations The number of vaccine recipients was limited and there was a considerable overlap of adverse effects with both vaccines. Voluntary reporting of cases is not an accurate representation of the scale of patients with adverse effects. Conclusion Rampant administration of vaccines along with widespread advertisement of vaccine-induced side effects via social media has created apprehension in the general population. This warrants studies improving awareness about the most vital preventive measure available to halt and eventually end the COVID-19 pandemic.
Collapse
Affiliation(s)
- Neerja Saraswat
- Department of Dermatology, Military Hospital, Agra, Uttar Pradesh, India
| | - Durga M. Tripathy
- Department of Dermatology, Military Hospital, Agra, Uttar Pradesh, India
| | - M Murali
- Department of Surgery, Command Hospital Air Force, Bengaluru, India
| | - Jahnabi Boruah
- Department of Dermatology, Jorhat Medical College & Hospital Assam, India
| | - Debdeep Mitra
- Department of Dermatology, Command Hospital Air Force, Bengaluru, Karnataka, India
| | - Harleen Chopra
- Department of Microbiology, Command Hospital Northern Command, Udhampur, Jammu and Kashmir, India
| | - Anuj Bhatnagar
- Department of Dermatology, Command Hospital Air Force, Bengaluru, Karnataka, India
| |
Collapse
|
3
|
Kumar R, Singh S, Chawla R, Balhara K, Dhar L. COVID-19 vaccination: Immune response in healthcare workers-A study with review of literature. INDIAN J PATHOL MICR 2023; 66:758-763. [PMID: 38084528 DOI: 10.4103/ijpm.ijpm_126_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Background As the world has been going through a pandemic of coronavirus disease 2019 (COVID-19) for the past two years, a safe and effective vaccine was urgently needed. Vaccination against the disease was launched in India on January 16, 2021 with healthcare workers, frontline workers, and the elderly above 60 years being the first beneficiaries. Vaccines being used in India are Covishield and Covaxin. Materials and Methods Fifteen healthcare workers (HCWs) who were vaccinated with Covishield or Covaxin were included in the study, and T cell, B cell and antibody response of the HCWs were analyzed. Blood samples collected from every subject were sent for antibody analysis, hematological workup for cell counts, and flow cytometry was performed for various subsets of lymphocytes. Hematological variables in naïve HCWs (who never had any natural infection) and recovered HCWs (those recovered from natural infection) were compared. Results Antibody index among recovered HCWs was significantly higher than the naïve HCWs. All the leucocyte parameters showed a higher median value in the recovered group except total leucocyte count (TLC), T helper cell count (Th cell), T helper cell to T cytotoxic cell (Th cell: CTL) ratio and natural killer (NK) cell. But only Th: CTL ratio showed a statistically significant difference. Conclusion This study shows that the antibody index among individuals who had both vaccination and COVID-19 infection is significantly higher than those who just had vaccination. T helper cell to T cytotoxic cell ratio is lowered in the recovered HCWs as compared to the naïve HCWs and this finding is statistically significant.
Collapse
Affiliation(s)
- Rabish Kumar
- Department of Pathology, Maulana Azad Medical College, New Delhi, India
| | - Sarika Singh
- Department of Pathology, Maulana Azad Medical College, New Delhi, India
| | - Rohit Chawla
- Department of Microbiology, Maulana Azad Medical College, New Delhi, India
| | - Kirti Balhara
- Department of Pathology, Maulana Azad Medical College, New Delhi, India
| | - Lity Dhar
- Department of Pathology, Maulana Azad Medical College, New Delhi, India
| |
Collapse
|
4
|
Pandit NB, Fulmali PR, Chandrayan P, Chauhan K, Bhil DL, Rasania MN. How safe is COVID-19 vaccination among pregnant women and its outcome - A hospital-based retrospective study in Indian population. J Family Med Prim Care 2023; 12:2140-2145. [PMID: 38024942 PMCID: PMC10657075 DOI: 10.4103/jfmpc.jfmpc_333_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Revised: 06/13/2023] [Accepted: 06/19/2023] [Indexed: 12/01/2023] Open
Abstract
Background Although getting the Covid infection is equal for every person, during pregnancy, the women's immunity is a little lower than usual, so they are more prone to infection. That is why they should be taken care of with more precautions. A vaccine is the best weapon to fight such infection. Covishield and Covaxin are the two vaccines first introduce in country India including for pregnant women. The safety of the vaccine was a big concern as one of them is a newer type of vaccine. The current study was planned with objectives to understand the safety aspect of Covid19 vaccine on pregnancy outcome and Adverse events following immunization (AEFI) following vaccination. Materials and Methods This was a hospital-based retrospective cohort study. The sample size was all the pregnant women who delivered a baby from July 2021 to April 2022 at the tertiary care hospital in Vadodara. These women were retrospectively assessed for the status of vaccination based on the record and other information related to ANC from the record. Total of 1974 women were eligible for study after inclusion-exclusion criteria. The collected data was analysed. Result Of the 1974 pregnant women, 531 (27%) took any of one covid19 vaccine and 1443 (73%) did not take vaccine. There were 511 (96%) women opted for Covishield vaccine and 20 (4%) women who opted for Covaxin. Of 531 women who took vaccination, 46% women had AEFI. The risk of low birth weight (LBW) baby was 40% among vaccinated v/s 39% among non-vaccinated and congenital malformation was 0.6% among vaccinated v/s 1% among non-vaccinated women. On the contrary, the risk of premature birth was 8% among the vaccinated group v/s 13% among the non-vaccinated group and NICU admission following delivery was 8% among the vaccinated group v/s 12% among the non-vaccinated group. Conclusion AEFI among pregnant women were found less compared to the general population. The study also revealed that both Covishield and Covaxin are found safe for pregnancy outcomes and can be given to pregnant women during any trimester of pregnancy message for a family physician.
Collapse
Affiliation(s)
- Niraj B. Pandit
- Department of Community Medicine, SBKS MI and RC, Sumandeep Vidypeeth, Vadodara, Gujarat, India
| | - Purvi R. Fulmali
- Department of Community Medicine Healthy Mother Healthy Child Project, Sumandeep Vidyapeeth, Vadodara, Gujarat, India
| | - Piyusha Chandrayan
- Department of Obstetrics and Gynaecology, Dhiraj Hospital, SBKS MIRC, Sumandeep Vidyapeeth, Vadodara, Gujarat, India
| | - Kishor Chauhan
- Department of Obstetrics and Gynaecology, Dhiraj Hospital, SBKS MIRC, Sumandeep Vidyapeeth, Vadodara, Gujarat, India
| | - Dipika L. Bhil
- Department of Paediatrics, Dhiraj Hospital, SBKS MIRC, Sumandeep Vidyapeeth, Vadodara, Gujarat, India
| | - Manish N. Rasania
- Department of Paediatrics, Dhiraj Hospital, SBKS MIRC, Sumandeep Vidyapeeth, Vadodara, Gujarat, India
| |
Collapse
|
5
|
Gupta SL, Goswami S, Anand A, Naman N, Kumari P, Sharma P, Jaiswal RK. An assessment of the strategy and status of COVID-19 vaccination in India. Immunol Res 2023; 71:565-577. [PMID: 37041424 PMCID: PMC10089693 DOI: 10.1007/s12026-023-09373-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Accepted: 03/14/2023] [Indexed: 04/13/2023]
Abstract
The COVID-19 disease continues to cause devastation for almost 3 years of its identification. India is one of the leading countries to set clinical trials, production, and administration of COVID-19 vaccination. Recent COVID-19 vaccine tracker record suggests that 12 vaccines are approved in India, including protein subunit, RNA/DNA, non-replicating viral vector, and inactivated vaccine. Along with that 16 more vaccines are undergoing clinical trials to counter COVID-19. The availability of different vaccines gives alternate and broad perspectives to fight against viral immune resistance and, thus, viruses escaping the immune system by mutations. Using the recently published literature on the Indian vaccine and clinical trial sites, we have reviewed the development, clinical evaluation, and registration of vaccines trial used in India against COVID-19. Moreover, we have also summarized the status of all approved vaccines in India, their associated registered clinical trials, manufacturing, efficacy, and their related safety and immunogenicity profile.
Collapse
Affiliation(s)
| | - Surbhi Goswami
- National Institute of Immunology, New Delhi, 110067 India
| | - Ananya Anand
- Department of Zoology, Patna Science College, Patna University, Bihar, India
| | - Namrata Naman
- Department of Zoology, Patna Science College, Patna University, Bihar, India
| | - Priya Kumari
- Department of Zoology, Patna Science College, Patna University, Bihar, India
| | - Priyanka Sharma
- Department of Zoology, Patna Science College, Patna University, Bihar, India
| | - Rishi K. Jaiswal
- Department of Cancer Biology, Cardinal Bernardin Cancer Center, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153 USA
| |
Collapse
|
6
|
Divas R, Prabhat R, Rohit R, Sanjay CA, Sushan H, Bijaya R. Covishield vaccination and pulmonary thromboembolism: A coincidence or a causal association? Clin Case Rep 2023; 11:e7468. [PMID: 37305866 PMCID: PMC10248195 DOI: 10.1002/ccr3.7468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2023] [Revised: 05/19/2023] [Accepted: 05/25/2023] [Indexed: 06/13/2023] Open
Abstract
With the eruption of COVID pandemic, many cases of thromboembolic events in association with the COVID infection were reported suggesting the prothrombotic state associated with the infection. After a few years, eventually some of the COVID vaccines came into implementation. With the discovery and implementation of COVID vaccinations, a very few cases have been reported to have developed thromboembolic events, including pulmonary thromboembolism. Different types of vaccines have been associated with different rates of thromboembolic events. Covishield vaccine is rarely associated with thrombotic complications. In the case report below, we present a case summary of a young married female, who presented with shortness of breath a week after the Covishield vaccination and presented to our tertiary care center with further worsening of symptoms during a course of 6 months. On detailed workup, she was diagnosed to have a large pulmonary thrombus affecting the left main pulmonary artery. Other possible etiologies of the hypercoagulable states were ruled out. Though COVID vaccines are known to induce prothrombotic state in the body, we could not be sure if it was the actual cause for the pulmonary thromboembolism or just a coincidence.
Collapse
Affiliation(s)
- Rijal Divas
- Department of Critical Care MedicineTribhuvan University Teaching HospitalMaharajgu, KathmanduNepal
| | - Rijal Prabhat
- Department of Internal MedicineAll India Institute of Medical SciencesRishikeshUttarakhandIndia
| | - Raina Rohit
- Department of Internal MedicineAll India Institute of Medical SciencesRishikeshUttarakhandIndia
| | - Chaudhari Ashish Sanjay
- Department of Internal MedicineAll India Institute of Medical SciencesRishikeshUttarakhandIndia
| | - Homagain Sushan
- Department of Critical Care MedicineTribhuvan University Teaching HospitalMaharajgu, KathmanduNepal
| | - Rawol Bijaya
- Department of Critical Care MedicineTribhuvan University Teaching HospitalMaharajgu, KathmanduNepal
| |
Collapse
|
7
|
Goruntla N, Karisetty B, Nandini N, Bhupasamudram B, Gangireddy HR, Veerabhadrappa KV, Ezeonwumelu JOC, Bandaru V. Adverse events following COVID-19 vaccination among pregnant women attending primary health centers: An active-surveillance study. Vacunas 2023:S1576-9887(23)00037-7. [PMID: 37362835 PMCID: PMC10192595 DOI: 10.1016/j.vacun.2023.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Revised: 05/02/2023] [Accepted: 05/05/2023] [Indexed: 06/28/2023]
Abstract
Introduction Vaccine safety is a major barrier to the uptake of the COVID-19 vaccine by pregnant women. To bring confidence among pregnant women towards vaccine intake, there is a need to synthesize evidence on safety profile of vaccination. Objective To assess adverse events (AEs) following COVID-19 vaccination among pregnant women. Materials and methods A vaccine safety surveillance was conducted at 2 rural primary health centers (PHC) located in Anantapur District, India. A total of 420 pregnant women were monitored for AEs following COVID-19 vaccination for a period of 30 min and followed for 1 month for late reactions through telephonic interviews. All AEs were subjected to causality and severity assessment. Descriptive statistics were used to represent adverse events. Results The COVID-19 vaccine acceptance rate among pregnant women was 64.4%. A total of 420 pregnant women received 670 vaccine doses (Covishield = 372, Covaxin = 298) against COVID-19. Majority of vaccine intake was observed during the second trimester. The incidence rate of AEs following the COVID-19 vaccine among pregnant women was 93.8%, and the majority include injection site pain (28.4%, 29.6%), fever (25.5%, 19.0%), myalgia (8.21%, 12.3%), and malaise (13.6%, 8.4%). Most AEs notified are probable and mild in nature. Conclusion The COVID-19 vaccine acceptance rate among pregnant women was 64.4%. A 30 days incidence rate of AEs following COVID-19 vaccination among pregnant women was 93.8%, with the most common mild events like injection site pain, and fever. A further follow-up cohort study by taking an adequate sample size was recommended to capture fetal-maternal outcomes.
Collapse
Affiliation(s)
- Narayana Goruntla
- Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy, Kampala International University, Western Campus, Uganda
| | - Basappa Karisetty
- Department of Pharmacy Practice, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) - Autonomous, Anantapur, Andhra Pradesh, India
| | - Nandini Nandini
- Department of Pharmacy Practice, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) - Autonomous, Anantapur, Andhra Pradesh, India
| | - Bharadwaj Bhupasamudram
- Department of Pharmacy Practice, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) - Autonomous, Anantapur, Andhra Pradesh, India
| | - Himaja Reddy Gangireddy
- Department of Pharmacy Practice, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) - Autonomous, Anantapur, Andhra Pradesh, India
| | | | | | - Vishnuvandana Bandaru
- Department of Pharmaceutical Analysis, Balaji College of Pharmacy, Anantapur, Andhra Pradesh, India
| |
Collapse
|
8
|
Vishnoi J, Sharma RK, Patel J, Sharma JC, Sharma KR, Mehta U. Severity and Outcome of Post-Vaccine COVID-19 among Healthcare Workers in a University Hospital in India. J Med Life 2023; 16:782-793. [PMID: 37520491 PMCID: PMC10375337 DOI: 10.25122/jml-2023-0017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2023] [Accepted: 03/29/2023] [Indexed: 08/01/2023] Open
Abstract
Healthcare workers (HCWs) are at high risk of COVID-19 infection despite vaccination. Limited data exist on COVID-19 cases among vaccinated HCWs. This study aimed to describe the clinical characteristics and outcomes of RT PCR-confirmed COVID-19 cases in vaccinated HCWs, at a COVID clinic in a medical college hospital. This single-center, prospective cohort study included HCWs who received at least one dose of the COVID-19 vaccine and tested positive for COVID-19 within 6 months. Data on demographics, symptoms, work category, COVID-19 vaccination interval, and infection severity were collected. Of 2381 vaccinated HCWs, 105 tested positive and were categorized as mild, moderate, or severe cases. Among vaccinated HCWs, 4.41% had post-vaccine COVID-19 infections. All 105 cases received the first dose, and 79 received the second dose. Of the cases, 47.6% were partially vaccinated, and 53.3% were breakthrough cases. The mean age was 30.90±8.69 years, with 63.8% male and 36.2% female cases. Most cases (85.7%) acquired infection in the hospital, and 47.6% had direct contact with COVID-19 patients. Common symptoms included fatigue (85.7%), fever (82.9%), and cough (64.8%). Among cases, 93.3% were mild, 5.7% were moderate, and 0.9% were severe. Hospital admission and supplemental oxygen therapy were required for moderate and severe cases. No mortality was reported. Certain variables were associated with age, preventive measures, workplace type, symptoms, and comorbidities. Breakthrough infections can occur among fully vaccinated HCWs but with reduced severity and mortality. Monitoring and infection control measures remain crucial even in vaccinated individuals. This study provides insights into clinical presentations, oxygen therapy requirements, and outcomes of post-vaccine COVID-19 cases among HCWs. The data will inform strategies for booster doses to prevent COVID-19.
Collapse
Affiliation(s)
- Jagdish Vishnoi
- Department of Medicine, Pacific Medical College and Hospital, Pacific Medical University, Udaipur, Rajasthan, India
| | - Rajendra Kumar Sharma
- Department of Pediatrics, Pacific Medical College and Hospital, Pacific Medical University, Udaipur, Rajasthan, India
| | - Japan Patel
- Department of Medicine, Pacific Medical College and Hospital, Pacific Medical University, Udaipur, Rajasthan, India
| | - Jagdish Chandra Sharma
- Department of Medicine, Pacific Medical College and Hospital, Pacific Medical University, Udaipur, Rajasthan, India
| | - Kalu Ram Sharma
- Department of Medicine, Pacific Medical College and Hospital, Pacific Medical University, Udaipur, Rajasthan, India
| | - Urvansh Mehta
- Department of Medicine, Pacific Medical College and Hospital, Pacific Medical University, Udaipur, Rajasthan, India
| |
Collapse
|
9
|
Fazili A, Ain SN, Shah RJ, Raja FN, Farhat D, Nazir I. Incidence of breakthrough infections after COVID-19 vaccination among the COVID-19 vaccine recipients at a Tertiary Care Hospital in Srinagar. Indian J Public Health 2023; 67:305-308. [PMID: 37459029 DOI: 10.4103/ijph.ijph_1403_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/20/2023] Open
Abstract
COVID-19 infections despite complete vaccination are called breakthrough infections. Breakthrough infections may decrease the vaccination confidence among people. This study was conducted soon after the Covishield vaccine was approved for use in J and K to find out the incidence of breakthrough infections among the recipients of the Covishield vaccine at SKIMS and to find out the associated factors. List of beneficiaries (between February 14, and May 15, 2021) was obtained from the records. Information was gathered telephonically. Incidence of breakthrough infections 6-month postvaccination was determined. Among 919 participants, the incidence of breakthrough infections was 2.7% (25 cases). The medical profession was associated with a higher frequency of breakthrough infections. Most infections were mild to moderate (96%). One (4%) person required hospitalization. Thus, COVID-19 infections can occur despite complete vaccination. Increased exposure places an individual at higher risk of breakthrough infections. Therefore, where exposure is high, COVID-appropriate behavior should be followed despite being vaccinated.
Collapse
Affiliation(s)
| | | | - Rohul Jabeen Shah
- Professor, Department of Community Medicine, SKIMS, Srinagar, Jammu and Kashmir, India
| | | | - Deeba Farhat
- Junior Resident, SKIMS, Srinagar, Jammu and Kashmir, India
| | - Isra Nazir
- Senior Resident, Department of Community Dentistry, SKIMS, Srinagar, Jammu and Kashmir, India
| |
Collapse
|
10
|
Thomas RE, Sukumaran A, Krishnan R A, Thomas T, Edwin BT, Haritha PR, Varghese BM, Paul JK, Kumar C S S, Vasudevan DM. Impact of Covishield Vaccination in Terms of SARS CoV-2 Neutralizing Antibody Expression. Indian J Clin Biochem 2023; 38:51-58. [PMID: 35465605 PMCID: PMC9012865 DOI: 10.1007/s12291-022-01030-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Accepted: 02/26/2022] [Indexed: 01/24/2023]
Abstract
The vaccination efficacy can indirectly be assessed through the quantification of neutralizing antibodies. Very few data are available on Covishield efficacy in terms of neutralizing antibody expression upon vaccination. This study is focused on profiling of neutralizing antibody expression during and after the Covishield two shot vaccination and observing COVID-19 infection in vaccinated participants during the period. SARS CoV-2 neutralizing antibody concentrations in samples were estimated using electrochemiluminescence immunoassay kit for Lifotronics eCL8000. The sampling had been done sequentially at 45th, 85th day after 1st dose and 15th day after 2nd dose Covishield vaccination. Parallelly, in order to confirm the total SARS CoV-2 IgG response in COVID-19 infection, measured the IgG using SARS CoV-2 IgG lateral flow immunoassay test kit. The subjects previously infected with COVID-19 before 1st dose vaccination demonstrated high neutralizing antibody (> 10AU/ml). In COVID-19 uninfected subjects, there was a sudden incline in neutralizing antibody after the 2nd dose. Infection with SARS CoV-2 between 1st and 2nd dose of Covishield vaccination implicate that the level of neutralizing antibody in serum after 1st dose was not adequate to combat the virus and prevent infection. We observed COVID-19 infection in participants even after 2nd dose of vaccination. Interestingly, there was no protection against SARS CoV-2 even with a high neutralizing antibody expression of 188.5 AU/mL after the 2nd dose. Findings of Covishield efficacy in different cohort samples before and after 2 doses of Covishield vaccination provide impetus for improvement or development of next generation vaccines.
Collapse
Affiliation(s)
- Rhema Elizabeth Thomas
- Agappe Diagnostics Limited, Research & Development Department, Agappe Hills, Pattimattom P O, Ernakulam, Kerala India
| | - Ajaikumar Sukumaran
- Agappe Diagnostics Limited, Research & Development Department, Agappe Hills, Pattimattom P O, Ernakulam, Kerala India
| | - Arun Krishnan R
- Agappe Diagnostics Limited, Research & Development Department, Agappe Hills, Pattimattom P O, Ernakulam, Kerala India
| | - Thushara Thomas
- Agappe Diagnostics Limited, Research & Development Department, Agappe Hills, Pattimattom P O, Ernakulam, Kerala India
| | - Biby T Edwin
- Agappe Diagnostics Limited, Research & Development Department, Agappe Hills, Pattimattom P O, Ernakulam, Kerala India
| | - P R Haritha
- Agappe Diagnostics Limited, Research & Development Department, Agappe Hills, Pattimattom P O, Ernakulam, Kerala India
| | - Bilha M Varghese
- Agappe Diagnostics Limited, Research & Development Department, Agappe Hills, Pattimattom P O, Ernakulam, Kerala India
| | - Jofy K Paul
- Agappe Diagnostics Limited, Research & Development Department, Agappe Hills, Pattimattom P O, Ernakulam, Kerala India
| | - Satheesh Kumar C S
- Agappe Diagnostics Limited, Research & Development Department, Agappe Hills, Pattimattom P O, Ernakulam, Kerala India
| | - D M Vasudevan
- Agappe Diagnostics Limited, Research & Development Department, Agappe Hills, Pattimattom P O, Ernakulam, Kerala India
| |
Collapse
|
11
|
Patel AK, Patel D, Shevkani M, Shah A, Madan S, Gohel S, Chhatwani C, Doshi A, Patel V, Sukhwani K, Kareliya H, Shah V, Savaj P, Rana M, Patel KK, Bakshi H. COVID-19 patients' clinical profile and outcome with respect to their vaccination status: A prospective observational multicentre cohort study during third wave in Western India. Indian J Med Microbiol 2023; 41:28-32. [PMID: 36870745 PMCID: PMC9793696 DOI: 10.1016/j.ijmmb.2022.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Revised: 07/17/2022] [Accepted: 12/14/2022] [Indexed: 12/28/2022]
Abstract
PURPOSE To understand the benefits of COVID-19 vaccination (Covishield, Covaxin) on clinical features and outcome of COVID-19 during the third wave in India. MATERIALS AND METHODS The primary study aim was to describe the clinical profile and outcome of COVID-19 regarding their vaccination and to identify risk factors for disease progression in vaccinated patients. This was a prospective observational multicentric study of COVID-19 attended by Infectious Disease physicians during January 15, 2022 to February 15, 2022. Adult patients with positive RT-PCR or rapid antigen test for COVID-19 were enrolled. Patient received treatment as per local institutional protocol. Chi square test for categorical and Mann Whitney test for continuous variables were applied for the analysis. Logistic regression was used to calculate adjusted odds ratios. RESULTS A total of 788 patients were included in analysis out of 883 enrolled patients from 13 centers across Gujarat. By the end of two weeks' follow up, 22 patients (2.8%) had expired. The Median age of subjects was 54 years, with a (55.8%) male. 90% of the subjects were vaccinated, majority (77%) of them had received 2 doses of vaccine with Covishield (659, 93%). Mortality among the non-vaccinated was significantly (11.4%) higher than vaccinated (1.8%). Logistic regression analysis showed numbers of comorbidities (p = 0.027), baseline higher WBC count (p = 0.02), higher NLR (p = 0.016), and Ct value (p = 0.046) were associated with mortality while vaccination was associated with survival (p = 0.001). The factors associated with mortality among vaccinated were age, comorbidities, baseline higher WBC, NLR, and CRP. CONCLUSIONS Omicron variant was associated with mild symptoms. Clinical and laboratory risk factors for getting severe disease with Omicron variant were the same with previous SARS CoV-2 strain. Two doses of vaccine protect people against severe disease and death. Age, comorbidities, baseline leucocytosis, high NLR, elevated CRP are the risk factors for poor outcome in vaccinated patients.
Collapse
Affiliation(s)
- Atul K Patel
- Infectious Diseases Department, Sterling Hospital, Ahmedabad 380052, India.
| | - Dhruv Patel
- Infectious Diseases and Tropical Medicine Clinic, Gala Business Center II, Off C G Road, Ahmedabad 380006, India
| | | | - Aniket Shah
- Infectious Diseases, Shraddha Hospital, 14 Harihar Society, Maninagar, Ahmedabad 380008, India
| | - Surabhi Madan
- Marengo CIMS Hospital, Off Science City Road, Sola, Ahmedabad, India
| | - Swati Gohel
- Narayana Multispeciality Hospital, Rakhiyal Cross Road, Rakhiyal, Ahmedabad 380023, India
| | - Chirag Chhatwani
- Ashirwad Infectious Disease Clinic (AIDC), 313-315, Zenon Apartment, Opp. Unique Hospital, Off. Ring Road, Surat 395007, India
| | | | - Vipul Patel
- Infectious Diseases Care Clinic (IDCC), 302 Shubham Super Speciality Hospital, Near Sardar Patel Statue, Ahmedabad 380013, India
| | | | | | - Vipul Shah
- Healthcare Infectious Diseases Clinic, 301, Sankalp Square 2, Near Kalgi Cross Road, Ellisbridge, Ahmedabad 380006, India
| | - Pratik Savaj
- 405, AXIS Business Space, Nanpura, Surat 395001, India
| | - Manish Rana
- Community Medicine Department, GMERS Medical College, Sola, Ahmedabad, Gujarat 380060, India
| | - Ketan K Patel
- Infectious Diseases Department, Sterling Hospital, Ahmedabad 380052, India
| | - Harsh Bakshi
- Community Medicine Department, GMERS Medical College, Sola, Ahmedabad, Gujarat 380060, India
| |
Collapse
|
12
|
Verma A, Goel A, Katiyar H, Tiwari P, Mayank, Sana A, Khetan D, Bhadauria DS, Raja A, Khokher N, Shalimar, Singh RK, Aggarwal A. Durability of ChAdOx1 nCoV-19 ( Covishield(®)) Vaccine Induced Antibody Response in Health Care Workers. Vaccines (Basel) 2022; 11. [PMID: 36679930 DOI: 10.3390/vaccines11010084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Revised: 12/23/2022] [Accepted: 12/28/2022] [Indexed: 01/03/2023] Open
Abstract
(i) Background: ChAdOx1 nCoV-19 (Covishield®) vaccine is widely used in India. We studied the Covishield® induced antibody response and its durability among health care workers (HCWs) (ii) Method: HCWs received two doses (0.5 mL) four weeks apart. Blood specimens, collected before each dose, day (D)60, D150 and D270 after second dose, were tested for anti-spike antibody (ASAb) titre and neutralising antibody (%) (NAb) using Elecsys Anti-SARS-CoV-2 S (Roche) and SARS-CoV-2 NAb ELISA Kit (Invitrogen), respectively. Data are expressed as proportions and median (interquartile range) and compared using non-parametric (iii) Result: Among 135 HCWs (83 males; age 45 (37−53); 36 had pre-existing ASAb), 29 (21.5%) acquired COVID-19 after 60 (39−68) days of vaccination. ASAb titre before second dose and at D60, D150, D270 were 77.2 (19.4−329.4), 512 (114.5−9212), 149 (51.6−2283) and 2079 (433.9−8644) U/mL, respectively. Compared to those without pre-existing ASAb, titres were significantly higher before second dose (5929 vs. 41, p < 0.001), D60 (3395 vs. 234, p = 0.007) and D150 (1805 vs. 103, p < 0.001) in participants with pre-existing ASAb; NAb were also higher (80 vs. 18, p < 0.001) before second dose. Between those who acquired infection or not after vaccination, ASAb titres were comparable before second dose (77 vs. 78, p = 0.362) but significantly higher at D60 (14,019 vs. 317, p < 0.001) and D150 (2062 vs. 121, p = 0.002) in the former group, though NAb percentage were higher at D60 (87 vs. 27, p < 0.001) and D150 (79 vs. 25, p = 0.007) only (iv) Conclusions: Covishield® induces a higher antibody titre in those with pre-existing ASAb. The vaccine induced antibody starts falling 5 months after vaccination.
Collapse
|
13
|
Jaggaiahgari S, Munigela A, Mitnala S, Gujjarlapudi D, Simhadri V, D NR. Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2. Vaccines (Basel) 2022; 10:vaccines10122146. [PMID: 36560556 PMCID: PMC9781398 DOI: 10.3390/vaccines10122146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Revised: 12/07/2022] [Accepted: 12/13/2022] [Indexed: 12/23/2022] Open
Abstract
Despite effective vaccination programs, waning immunity in the vaccinated populations and the emergence of variants of concern posed a risk of breakthrough infections. A booster dose was demonstrated to provide substantially increased protection against symptomatic disease and hospitalization. We aimed to evaluate immune memory and the efficacy of reducing the rate of SARS-CoV-2 infection post heterologous booster with CORBEVAX after primary vaccination with two doses of COVISHIELD. SARS-CoV-2 S1/S2 spike IgG and RBD-specific antibody responses were elicited with both booster vaccines, with a greater response in individuals receiving heterologous booster. T and B memory responses were increased with booster dose, whereas B memory needed a longer duration to develop in individuals who received a homologous booster (90 days) in comparison to a heterologous booster (30 days). RBD-specific B memory and antibody-secreting (non-memory) B lymphocytes were enhanced with both boosters; however, the duration of response was longer with the heterologous booster compared to the homologous, indicating greater protection with the heterologous booster. The rate of infection 14 days after administration of the heterologous booster was comparatively lower than that of the homologous booster, with the symptoms being much less or asymptomatic.
Collapse
Affiliation(s)
- Shashidhar Jaggaiahgari
- Institute of Translational Research, Asian Healthcare Foundation, AIG Hospitals, Hyderabad 500032, India
| | - Apoorva Munigela
- Department of Internal Medicine, AIG Hospitals, Hyderabad 500032, India
| | - Sasikala Mitnala
- Institute of Translational Research, Asian Healthcare Foundation, AIG Hospitals, Hyderabad 500032, India
- Correspondence:
| | | | - Venu Simhadri
- Institute of Translational Research, Asian Healthcare Foundation, AIG Hospitals, Hyderabad 500032, India
| | - Nageshwar Reddy D
- Institute of Translational Research, Asian Healthcare Foundation, AIG Hospitals, Hyderabad 500032, India
| |
Collapse
|
14
|
Jhaj R, Chaudhary D, Shukla AK, Yadav J. Stimulated Reporting of Adverse Events Following Immunization with COVID-19 Vaccines. Vaccines (Basel) 2022; 10. [PMID: 36560545 DOI: 10.3390/vaccines10122133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2022] [Revised: 12/01/2022] [Accepted: 12/07/2022] [Indexed: 12/15/2022] Open
Abstract
In India, up until December 2021, Covishield and Covaxin vaccines against COVID-19 were being used for mass vaccination programs. In view of the urgency of fighting the ongoing pandemic, many vaccines have been granted emergency use approval while phase 2/3 clinical trials were still underway. Even for vaccines that have completed phase 3 trials, safety data may not be comprehensive. This retrospective observational study was conducted at a designated Regional Training Centre for Pharmacovigilance cum Adverse Drug Reaction Monitoring Centre (AMC) under the Pharmacovigilance Programme of India. The data sources were stimulated spontaneous reports of Adverse Events Following Immunization (AEFI) due to the COVID-19 vaccines from 10 January to 31 December 2021. A total of 51,010 COVID vaccine doses were administered during the study period. There were 330 AEFI reported (AEFI rate: 0.65%). Six AEFI were serious events among which three were Adverse Events of Special Interest. The majority of the AEFI were systemic, reported after the first dose, and with an onset between 1 and 24 h after vaccination. On comparing Covishield and Covaxin, there were no statistically significant differences in the AEFI reported with either vaccine in terms of gender, seriousness, lag period, duration, recovery, causality, treatment received for AEFI, presence of co-morbidity, or history of COVID-19 infection. Overall, the rates of AEFI was uncommon, and serious AEFI were rare with both Covishield and Covaxin, with a higher rate after the first dose. Whether immunological tolerance or allayed anxiety was responsible for the lower AEFI risk with the second dose remains to be investigated.
Collapse
|
15
|
Arthi M, Dabir S, Khatri M, Rajan M. Bilateral choroidal effusion following vaccination against SARS-CoV-2 virus. Indian J Ophthalmol 2022; 70:4449-4450. [PMID: 36453364 PMCID: PMC9940547 DOI: 10.4103/ijo.ijo_946_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
An 80-year-old systemically stable female presented with sudden blurring of vision post the first dose of CovishieldTM, a non-replicating viral vector vaccine. On examination, she was found to have bilateral serous choroidal effusions. A thorough systemic and ocular workup was performed to rule out other causes of choroidal effusion. The effusions resolved with tapering doses of oral and systemic steroids. To the best of our knowledge, at the time of submission, this is the first case of choroidal effusion being reported after the coronavirus disease 2019 (COVID-19) vaccine.
Collapse
Affiliation(s)
- M Arthi
- Department of Retina and Vitreous, Rajan Retina Foundation, Rajan Eye Care Hospital, Chennai, Tamil Nadu, India,Correspondence to: Dr. Arthi Mohankumar, Rajan Eye Care Hospital Pvt Ltd, 5, Vidyodaya Second Street, T. Nagar, Chennai - 600 017, Tamil Nadu, India. E-mail:
| | - Supriya Dabir
- Department of Retina and Vitreous, Rajan Retina Foundation, Rajan Eye Care Hospital, Chennai, Tamil Nadu, India
| | - Manoj Khatri
- Department of Retina and Vitreous, Rajan Retina Foundation, Rajan Eye Care Hospital, Chennai, Tamil Nadu, India
| | - Mohan Rajan
- Department of Retina and Vitreous, Rajan Retina Foundation, Rajan Eye Care Hospital, Chennai, Tamil Nadu, India
| |
Collapse
|
16
|
Shete AM, Patil DY, Sahay RR, Sapkal GN, Deshpande GR, Yadav PD. Waning natural and vaccine-induced immunity leading to reinfection with SARS-CoV-2 Omicron variant. Hum Vaccin Immunother 2022; 18:2127289. [PMID: 36170667 DOI: 10.1080/21645515.2022.2127289] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
We have investigated six COVID-19 recovered cases with two doses of Covishield vaccination followed by reinfection. The primary SARS-CoV-2 infection found to occur with B.1 and reinfection with Omicron BA.1 and BA.2 variants. The genomic characterization and duration between two infections confirms these cases as SARS-CoV-2 reinfection. The immune response determined at different time intervals demonstrated boost post two dose vaccination, decline in pre-reinfection sera post 7 months and rise post reinfection. In conclusion, it was observed that these cases got SARS-CoV-2 reinfection with declined hybrid immunity acquired from primary infection and two dose covishield vaccination. This findings suggests the need to protect the community through booster dose of vaccination and prevent further infections following personal hygiene and non-pharmaceutical interventions.
Collapse
Affiliation(s)
- Anita M Shete
- Indian Council of Medical Research-National Institute of Virology, Pune, India
| | - Deepak Y Patil
- Indian Council of Medical Research-National Institute of Virology, Pune, India
| | - Rima R Sahay
- Indian Council of Medical Research-National Institute of Virology, Pune, India
| | - Gajanan N Sapkal
- Indian Council of Medical Research-National Institute of Virology, Pune, India
| | - Gururaj R Deshpande
- Indian Council of Medical Research-National Institute of Virology, Pune, India
| | - Pragya D Yadav
- Indian Council of Medical Research-National Institute of Virology, Pune, India
| |
Collapse
|
17
|
Goel A, Verma A, Tiwari P, Katiyar H, Aggarwal A, Khetan D, Mayank, Kishore RVK, Kumar P, Singh TP, Sheikh S, Vaishnav M, Pathak P, Shalimar. Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine ( Covishield(®)) in Patients with Liver Cirrhosis. Vaccines (Basel) 2022; 10. [PMID: 36366346 DOI: 10.3390/vaccines10111837] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Revised: 10/26/2022] [Accepted: 10/27/2022] [Indexed: 11/17/2022] Open
Abstract
Introduction: Data are limited on antibody response to the ChAdOx1 nCoV-19 vaccine (AZD1222; Covishield®) in cirrhosis. We studied the antibody response following two doses of the ChAdOx1 vaccine, given 4−12 weeks apart, in cirrhosis. Methods: Prospectively enrolled, 131 participants (71% males; age 50 (43−58); alcohol-related etiology 14, hepatitis B 33, hepatitis C 46, cryptogenic 21, autoimmune 9, others 8; Child−Turcott−Pugh class A/B/C 52/63/16). According to dose intervals, the participants were grouped as ≤6 weeks (group I), 7−12 weeks (group II), and 13−36 weeks (group III). Blood specimens collected at ≥4 weeks after the second dose were tested for anti-spike antibody titre (ASAb; positive ≥ 0.80 U/mL) and neutralizing antibody (NAb; positive ≥20% neutralization) using Elecsys Anti-SARS-CoV-2 S (Roche) and SARS-CoV-2 NAb ELISA Kit (Invitrogen), respectively. Data are expressed as number (proportion) and median (interquartile range) and compared using non-parametric tests. Results: Overall, 99.2% and 84% patients developed ASAb (titre 5440 (1719−9980 U/mL)) and NAb (92 (49.1−97.6%)), respectively. When comparing between the study groups, the ASAb titres were significantly higher in group II than in group I (2613 (310−7518) versus 6365 (2968−9463), p = 0.027) but were comparable between group II and III (6365 (2968−9463) versus 5267 (1739−11,653), p = 0.999). Similarly, NAb was higher in group II than in group I (95.5 (57.6−98.0) versus 45.9 (15.4−92.0); p < 0.001), but not between the groups II and III (95.5 (57.6−98.0) versus 92.4 (73.8−97.5); p = 0.386). Conclusion: Covishield® induces high titres of ASAb and NAb in cirrhosis. A higher titre is achieved if two doses are given at an interval of more than six weeks.
Collapse
|
18
|
Bhadauria DS, Katiyar H, Goel A, Tiwari P, Kishore RVK, Aggarwal A, Verma A, Khetan D, Kaul A, Yachha M, Behera MR, Yadav B, Prasad N. Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients. Vaccines (Basel) 2022; 10:vaccines10101693. [PMID: 36298558 PMCID: PMC9610051 DOI: 10.3390/vaccines10101693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2022] [Revised: 09/29/2022] [Accepted: 10/08/2022] [Indexed: 11/16/2022] Open
Abstract
Kidney transplant recipients (KTRs) are at a much higher risk of complications and death following COVID-19 and are poor vaccine responders. The data are limited on the immune response to Covishield® in KTRs. We prospectively recruited a cohort of 67 KTRs aged >18 between April 2021 and December 2021. Each participant was given two intramuscular doses of Covishield®, each of 0.5 mL, at an interval of 12 weeks. A blood specimen of 5.0 mL was collected from each participant at two points within a few days before administering the first dose of the vaccine and at any time between 4−12 weeks after administering the second dose. The sera were tested for anti-RBD antibody (ARAb) titre and neutralising antibody (NAb). An ACE2 competition assay was used as a proxy for virus neutralization. According to the prior COVID-19 infection, participants were grouped as (i) group A: prior symptomatic COVID-19 infection, (ii) group B: prior asymptomatic COVID-19 infection as evidenced by detectable ARAb in the prevaccination specimen, (iii) Group C: no prior infection with COVID-19, (iv) group D: Unclassified, i.e., participants had no symptoms suggestive of COVID-19, but their prevaccination specimen was not available for ARAb testing before vaccination. Fifty of sixty-seven participants (74.6%) provided paired specimens (group A 14, group B 27, and group C 9) and 17 participants (25.4%) provided only postvaccination specimens (group D). In the overall cohort (n = 67), 91% and 77.6% of participants developed ARAb and NAb, respectively. Their ARAb titre and NAb proportion were 2927 (520−7124) U/mL and 87.9 (24.4−93.2) %, respectively. Their median ARAb titre increased 65.6 folds, from 38.2 U/mL to 3137 U/mL. Similarly, the proportion of participants with NAb increased from 56% to 86%, and the NAb proportion raised 2.7 folds, from 23% to 91%. A comparison of vaccine response between the study groups showed that all those with or without prior COVID-19 infection showed a significant rise in ARAb titre (p < 0.05) and NAb proportion (p < 0.05) after the two doses of vaccine administration. The median value of folds rise in anti-RBD and NAb between groups A and B were comparable. Hence, ARAb is present in more than 3/4th of KTRs before the ChAdOx1 vaccine in India. The titer of ARAb and the proportion of NAb significantly increased after the two doses of the ChAdOx1 vaccine in KTRs.
Collapse
Affiliation(s)
- Dharmendra S. Bhadauria
- Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
| | - Harshita Katiyar
- Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
| | - Amit Goel
- Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
- Correspondence:
| | - Prachi Tiwari
- Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
| | - Ravi V. Krishna Kishore
- Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
| | - Amita Aggarwal
- Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
| | - Alka Verma
- Department of Emergency Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
| | - Dheeraj Khetan
- Department of Transfusion medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
| | - Anupma Kaul
- Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
| | - Monika Yachha
- Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
| | - Manas Ranjan Behera
- Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
| | - Brijesh Yadav
- Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
| | - Narayan Prasad
- Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
| |
Collapse
|
19
|
Vanlalduhsaki, Roy S, Laldinmawii G, Patki SM, Sundaram SP. Vaccination and COVID-19 infection among adults aged 45 years and above in a North-Eastern state of India. J Family Med Prim Care 2022; 11:6375-6379. [PMID: 36618201 PMCID: PMC9810973 DOI: 10.4103/jfmpc.jfmpc_506_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Revised: 05/31/2022] [Accepted: 06/16/2022] [Indexed: 11/11/2022] Open
Abstract
Background In response to this coronavirus disease 2019 (COVID-19) pandemic, vaccines reaching the predetermined levels of safety and efficacy were rolled out for use under emergency use approval/listing (EUA/EUL). The government of India has introduced three vaccines for emergency use as of today. Aim The study was conducted to evaluate the association between the Covishield vaccine and COVID-19 infection among adults (≥45 years) who undergo reverse transcription-polymerase chain reaction (RT-PCR) COVID-19 testing. Methods The study was conducted in a dedicated COVID-19 hospital in a north-eastern state of India among adults aged 45 years and above, who underwent RT-PCR testing. Cases were those who tested positive for RT-PCR and controls were those who were RT-PCR negative during the same period. A structured questionnaire was used to collect relevant data pertaining to socio-demographic profile, symptoms of COVID-19, vaccination status, co-morbidities, etc. Multiple logistic regression was used to calculate the odds ratio (OR) to find the association between vaccination and COVID-19 infection. Results A total of 116 participants, 45 years and above were interviewed in the study. It was found that cases were more likely to have symptoms (48% vs. 6.9%, P value = <0.005) and have history of positive family member (89.7% vs. 72.4%, P value = 0.018) than controls. The odds of having COVID-19 infection were OR 12.60 (95% confidence interval (CI) 4.03-39.34) for those that have symptoms and OR 6.07 (95% CI 1.90-19.34) for unvaccinated individuals. Conclusions Covishield vaccine protected individuals against COVID-19 infection with the risk of getting the infection being significantly lower in vaccinated individuals. Relevance for Patients: COVID-19 vaccination prevents the infection and addresses misconceptions about the vaccine.
Collapse
Affiliation(s)
- Vanlalduhsaki
- Department of Community Medicine, Zoram Medical College, Falkawn, Mizoram, India,Address for correspondence: Dr. Vanlalduhsaki, Department of Community Medicine, Zoram Medical College, Falkawn - 796 005, Mizoram, India. E-mail:
| | - Swagnik Roy
- Department of Microbiology, Zoram Medical College, Falkawn, Mizoram, India
| | - Gracy Laldinmawii
- Department of Microbiology, Zoram Medical College, Falkawn, Mizoram, India
| | - Swati M. Patki
- Department of Community Medicine, Zoram Medical College, Falkawn, Mizoram, India
| | | |
Collapse
|
20
|
Sahoo SS, Kaur N, Kaur A, Garg S. Lymphadenopathy subsequent to Covishield (ChAdOx1 nCoV-19) Corona virus vaccine: ultrasound findings and clinical implications. Ther Adv Vaccines Immunother 2022; 10:25151355221124018. [PMID: 36133302 PMCID: PMC9482933 DOI: 10.1177/25151355221124018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Accepted: 08/12/2022] [Indexed: 11/17/2022] Open
Abstract
Introduction Post anti-COVID-19 vaccine lymphadenopathies have been recently described in literature, from different parts of the world. Although there have been studies on lymphadenopathy following mRNA vaccines, there is a paucity of studies on lymphadenopathy following inactivated viral vaccines, such as Covishield. Aim In this study, we explored lymphadenopathy subsequent to Covishield vaccine in terms of its various ultrasound parameters in the Indian population. Methods This hospital-based longitudinal study was conducted among 50 adult beneficiaries of Covishield vaccine. Sociodemographic details and relevant clinical history were recorded using a semi-structured performa. Detailed ultrasound (USG) examination of the bilateral axillae was done on the day of vaccination and after 6-12 days post vaccination. Vaccine beneficiaries were evaluated for the presence of any vaccine-associated lymphadenopathy and described the presence, number, size, morphology, cortical thickness, and presence or absence of echogenic hilum. Results Out of total (63) lymph nodes evaluated sonologically, majority (80.9%) of lymph nodes showed the features of benign lymphadenopathy. However, 12.6% (8/63) lymph nodes showed diffusely thickened cortex with preserved central echogenic hilum, 4.76% (3/63) lymph nodes showed eccentric cortical thickness with preserved hilar pattern, while only one lymph node showed diffuse cortical thickening with loss of central echogenic hilum. Conclusion With an increase in vaccination coverage, clinicians are likely to confront increasing cases of vaccine-associated axillary lymphadenopathy. Therefore, they should exercise care, that contemporary anti-COVID-19 vaccination can present an aetiology of axillary lymph nodes with suspicious USG features.
Collapse
Affiliation(s)
- Soumya Swaroop Sahoo
- Department of Community and Family Medicine, All India Institute of Medical Sciences, Bathinda, Punjab, India
| | - Navdeep Kaur
- Assistant Professor, Department of Radiodiagnosis, All India Institute of Medical Sciences, Bathinda, 151001, Punjab, India
| | - Amandeep Kaur
- Department of General Medicine, All India Institute of Medical Sciences, Bathinda, Punjab, India
| | - Shivane Garg
- Department of Radiodiagnosis, All India Institute of Medical Sciences, Bathinda, Punjab, India
| |
Collapse
|
21
|
Ahmed TI, Rishi S, Irshad S, Aggarwal J, Happa K, Mansoor S. Inactivated vaccine Covaxin/BBV152: A systematic review. Front Immunol 2022; 13:863162. [PMID: 36016940 PMCID: PMC9395719 DOI: 10.3389/fimmu.2022.863162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Accepted: 06/27/2022] [Indexed: 11/13/2022] Open
Abstract
We systematically reviewed and summarized studies focusing on Bharat Biotech’s Whole Virion Inactivated Corona Virus Antigen BBV152 (Covaxin), which is India’s indigenous response to fighting the SARS-CoV-2 pandemic. Studies were searched for data on the efficacy, immunogenicity, and safety profile of BBV152. All relevant studies published up to March 22, 2022, were screened from major databases, and 25 studies were eventually inducted into the systematic review. The studies focused on the virus antigen (6 μg) adjuvanted with aluminium hydroxide gel and/or Imidazo quinolin gallamide (IMDG), aTLR7/8 agonist. Pre-clinical, phase I, and II clinical trials showed appreciable immunogenicity. Both neutralizing and binding antibody titers were significant and T cell responses were Th1-biased. Phase III trials on the 6 μg +Algel-IMDG formulation showed a 93.4% efficacy against severe COVID-19. Data from the trials revealed an acceptable safety profile with mostly mild-moderate local and systemic adverse events. No serious adverse events or fatalities were seen, and most studies reported milder and lesser adverse events with Covaxin when compared with other vaccines, especially Oxford-Astra Zeneca’s AZD1222 (Covishield). The immunogenicity performance of Covaxin, which provided significant protection only after the second dose, was mediocre and it was consistently surpassed by Covishield. One study reported adjusted effectiveness against symptomatic infection to be just 50% at 2 weeks after the second dose. Nonetheless, appreciable results were seen in previously infected individuals administered both doses. There was some evidence of coverage against the Alpha, Beta, and Delta variants. However, neither Covaxin nor Covishield showed sufficient protection against the Omicron variant. Two studies reported super-additive results on mixing Covaxin with Covishield. Further exploration of heterologous prime-boost vaccination with a combination of an inactivated vaccine and an adenoviral vector-based vaccine for tackling future variants may be beneficial.
Collapse
Affiliation(s)
- Tousief Irshad Ahmed
- Department of Clinical Biochemistry, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, JK, India
| | - Saqib Rishi
- Department of Microbiology, Government Medical College, Srinagar, JK, India
| | - Summaiya Irshad
- Department of Ophthalmology, Government Medical College, Jammu, JK, India
| | - Jyoti Aggarwal
- Department of Biochemistry, Maharishi Markandeshwar Institute of Medical Sciences and Research (MMIMSR), Ambala, HR, India
| | - Karan Happa
- Department of General Medicine, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, JK, India
| | - Sheikh Mansoor
- Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, JK, India
| |
Collapse
|
22
|
Sarraf TR, Maity S, Ghosh A, Bhattacharjee S, Pani A, Saha K, Chattopadhyay D, Ghosh G, Sen M. Immune Response to COVID-19 in India through Vaccination and Natural Infection. Fortune J Health Sci 2022; 5:432-454. [PMID: 37304053 PMCID: PMC10257406 DOI: 10.26502/fjhs.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
In India, COVID-19 (Corona Virus Disease-2019) continues to this day, although with subdued intensity, following two major waves of viral infection. Despite ongoing vaccination drives to curb the spread of COVID-19, the relative potential of the administered vaccines to render immune protection to the general population and their advantage over natural infection remain undocumented. In this study, we examined the humoral and cell-mediated immune responses induced by the two vaccines Covishield and Covaxin, in individuals living in and around Kolkata, India. We also compared the immune responses induced separately by vaccination and natural infection. Our results indicate that although Covishield generates a better humoral immune response toward SARS-CoV-2, both vaccines are almost equivalent in terms of cell-mediated immune response to the virus. Both Covishield and Covaxin, however, are more effective toward the wild-type virus than the Delta variant. Additionally, the overall immune response resulting from natural infection in and around Kolkata is not only similar to that generated by vaccination but the cell-mediated immune response to SARS-CoV-2 also lasts for at least ten months in some individuals after the viral infection.
Collapse
Affiliation(s)
- Tresa Rani Sarraf
- CSIR-Indian Institute of Chemical Biology, 4 Raja Subodh Chandra Mullick Road, Kolkata 700032
| | - Shreyasi Maity
- CSIR-Indian Institute of Chemical Biology, 4 Raja Subodh Chandra Mullick Road, Kolkata 700032
| | - Arjun Ghosh
- Biobharati Life Sciences, EN-35, Sector V, Kolkata 700091
| | | | - Arijit Pani
- Biobharati Life Sciences, EN-35, Sector V, Kolkata 700091
| | - Kaushik Saha
- University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093
| | | | - Gourisankar Ghosh
- University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093
| | - Malini Sen
- CSIR-Indian Institute of Chemical Biology, 4 Raja Subodh Chandra Mullick Road, Kolkata 700032
| |
Collapse
|
23
|
Murali S, Sakthivel M, Pattabi K, Venkatasamy V, Thangaraj JWV, Shete A, Varghese AJ, Arjun J, Kumar CPG, Yadav PD, Sahay R, Majumdar T, Dudhmal M, Sivalingam A, Dhanapal SR, Durai Samy A, Radhakrishnan V, Muni Krishnaiah MM, Arunachalam S, Gandhi PMK, Govindasamy E, Chinnappan P, Sekar DPV, Marappan P, Pounraj E, Ganeshkumar P, Jagadeesan M, Narnaware M, Bedi GS, Kaur P, Murhekar M. Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine ( CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021. Vaccines (Basel) 2022; 10:970. [PMID: 35746578 DOI: 10.3390/vaccines10060970] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Revised: 06/06/2022] [Accepted: 06/14/2022] [Indexed: 12/20/2022] Open
Abstract
We estimated the effectiveness of two doses of the ChAdOx1 nCoV-19 (Covishield) vaccine against any COVID-19 infection among individuals ≥45 years in Chennai, Tamil Nadu, India. A community-based cohort study was conducted from May to September 2021 in a selected geographic area in Chennai. The estimated sample size was 10,232. We enrolled 69,435 individuals, of which 21,793 were above 45 years. Two-dose coverage of Covishield in the 18+ and 45+ age group was 18% and 31%, respectively. Genomic analysis of 74 out of the 90 aliquots collected from the 303 COVID-19-positive individuals in the 45+ age group showed delta variants and their sub-lineages. The vaccine’s effectiveness against COVID-19 disease in the ≥45 age group was 61.3% (95% CI: 43.6–73.4) at least 2 weeks after receiving the second dose of Covishield. We demonstrated the effectiveness of two doses of the ChAdOx1 vaccine against the delta variant in the general population of Chennai. We recommend similar future studies considering emerging variants and newer vaccines. Two-dose vaccine coverage could be ensured to protect against COVID-19 infection.
Collapse
|
24
|
Das S, Kar SS, Samanta S, Banerjee J, Giri B, Dash SK. Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. Immunol Res 2022; 70:289-315. [PMID: 35192185 PMCID: PMC8861611 DOI: 10.1007/s12026-022-09265-0] [Citation(s) in RCA: 26] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2021] [Accepted: 01/17/2022] [Indexed: 02/07/2023]
Abstract
SARS-CoV-2 is an RNA virus that was identified for the first time in December 2019 in Wuhan, China. The World Health Organization (WHO) labeled the novel coronavirus (COVID-19) outbreak a worldwide pandemic on March 11, 2020, due to its widespread infectivity pattern. Because of the catastrophic COVID-19 outbreak, the development of safe and efficient vaccinations has become a key priority in every health sector throughout the globe. On the 13th of January 2021, the vaccination campaign against SARS-CoV-2 was launched in India and started the administration of two types of vaccines known as Covaxin and Covishield. Covishield is an adenovirus vector-based vaccine, and Covaxin was developed by a traditional method of vaccine formulation, which is composed of adjuvanted inactivated viral particles. Each vaccine's utility or efficiency is determined by its formulation, adjuvants, and mode of action. The efficacy of the vaccination depends on numeral properties like generation antibodies, memory cells, and cell-mediated immunity. According to the third-phase experiment, Covishield showed effectiveness of nearly 90%, whereas Covaxin has an effectiveness of about 80%. Both vaccination formulations in India have so far demonstrated satisfactory efficacy against numerous mutant variants of SARS-CoV-2. The efficacy of Covishield may be diminished if the structure of spike (S) protein changes dramatically in the future. In this situation, Covaxin might be still effective for such variants owing to its ability to produce multiple antibodies against various epitopes. This study reviews the comparative immunogenic and therapeutic efficacy of Covaxin and Covishield and also discussed the probable vaccination challenges in upcoming days.
Collapse
Affiliation(s)
- Swarnali Das
- Department of Physiology, University of Gour Banga, Malda, 732103, West Bengal, India
| | - Suvrendu Sankar Kar
- Department of Medicine, R.G.Kar Medical College, Kolkata, 700004, West Bengal, India
| | - Sovan Samanta
- Department of Physiology, University of Gour Banga, Malda, 732103, West Bengal, India
| | - Jhimli Banerjee
- Department of Physiology, University of Gour Banga, Malda, 732103, West Bengal, India
| | - Biplab Giri
- Department of Physiology, University of Gour Banga, Malda, 732103, West Bengal, India
| | - Sandeep Kumar Dash
- Department of Physiology, University of Gour Banga, Malda, 732103, West Bengal, India.
| |
Collapse
|
25
|
Sapkal G, Kant R, Dwivedi G, Sahay RR, Yadav PD, Deshpande GR, Singh R, Nyayanit DA, Patil DY, Shete-Aich AM, Zaman K, Chaudhari AK, Gupta N, Panda S, Abraham P, Bhargava B. Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine. J Travel Med 2022; 29:6542352. [PMID: 35244698 PMCID: PMC8903478 DOI: 10.1093/jtm/taac033] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Revised: 02/17/2022] [Accepted: 01/18/2022] [Indexed: 12/03/2022]
Abstract
Comparative analysis at one- and six-months post-vaccination showed modest reduction in S1-RBD IgG antibody and NAb titers against B.1, Alpha, Beta and Delta variants in heterologous and homologous vaccine recipients groups. However, significant reduction in NAb titers against Omicron in vaccinees’ sera post-six months underlines need for cautious prospective follow-up.
Collapse
Affiliation(s)
- Gajanan Sapkal
- Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India
| | - Rajni Kant
- Indian Council of Medical Research-Regional Medical Research Centre (RMRC), Gorakhpur, Uttar Pradesh, 273013, India
| | - Gaurav Dwivedi
- Indian Council of Medical Research-Regional Medical Research Centre (RMRC), Gorakhpur, Uttar Pradesh, 273013, India
| | - Rima R Sahay
- Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India
| | - Pragya D Yadav
- Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India
| | - Gururaj R Deshpande
- Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India
| | - Rajeev Singh
- Indian Council of Medical Research-Regional Medical Research Centre (RMRC), Gorakhpur, Uttar Pradesh, 273013, India
| | - Dimpal A Nyayanit
- Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India
| | - Deepak Y Patil
- Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India
| | - Anita M Shete-Aich
- Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India
| | - Kamran Zaman
- Indian Council of Medical Research-Regional Medical Research Centre (RMRC), Gorakhpur, Uttar Pradesh, 273013, India
| | - Anil K Chaudhari
- Chief Medical Officer, Community Health Centre, Siddarthnagar, Uttar Pradesh, 272207, India
| | - Nivedita Gupta
- Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi, 110029, India
| | - Samiran Panda
- Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi, 110029, India
| | - Priya Abraham
- Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India
| | - Balram Bhargava
- Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi, 110029, India
| |
Collapse
|
26
|
Pramod S, Govindan D, Ramasubramani P, Kar SS, Aggarwal R. Effectiveness of Covishield vaccine in preventing Covid-19 - A test-negative case-control study. Vaccine 2022; 40:3294-3297. [PMID: 35168838 PMCID: PMC8825308 DOI: 10.1016/j.vaccine.2022.02.014] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Revised: 01/09/2022] [Accepted: 02/02/2022] [Indexed: 01/17/2023]
Abstract
INTRODUCTION This study aimed at assessing the vaccine effectiveness (VE) of Covishield, which is identical to AstraZeneca vaccine, in preventing laboratory-confirmed Covid-19. METHODS Using test-negative case-control design, information on vaccination status of cases with Covid-19 among healthcare workers in our institution in Puducherry, India, and an equal number of controls matched for age and date of testing, was obtained. The groups were compared using multivariable conditional logistic regression to calculate odds ratios (OR). VE was calculated as 100*(1-adjusted odds ratio)%. RESULTS Using data from 360 case-control pairs, VE of one dose and of two doses, in providing protection against Covid-19 was 49% (95% CI: 17%-68%) and 54% (27%-71%), respectively. Among cases with moderately severe disease that required oxygen therapy, VE following any number of vaccine doses was 95% (44%-100%). CONCLUSION Covishield vaccine protected significantly against Covid-19, with a higher protection rate against severe forms of disease.
Collapse
|
27
|
Poudel KM, Shah N, Prakash M, Deo SK, Bhandari S, Poudel TR. Determinants of associated events following AZD1222 ( Covishield) vaccination in a high-risk population in Nepal. BMC Infect Dis 2022; 22:422. [PMID: 35505278 PMCID: PMC9062853 DOI: 10.1186/s12879-022-07406-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Accepted: 04/19/2022] [Indexed: 12/23/2022] Open
Abstract
Background Vaccination is the most effective method to prevent the spread of infectious diseases and helps reduce mortality rate and economic costs associated with the pandemic. Despite these advantages, misinformation on vaccine safety and efficacy can lead to increased hesitation towards vaccination. This study reports the incidence of adverse events following Covishield vaccination, their associated factors, medication used for their management, and attitudes about vaccine safety. Methods A cross-sectional study was conducted from the sample of Covishield-vaccinated individuals from a secondary hospital, two primary health centres, and 36 health posts in eastern Nepal. Individuals (n = 602) were randomly sampled from a population (n = 1013) who had received the first dose of Covishield, namely frontline workers and other high-risk populations. The second-round follow-up had 516 participants. Association of incidence and severity of post-vaccination events with socio-demographic variables, comorbidity status, and medication use were estimated. Results Among the 79.9% of participants who reported adverse events after receiving the first dose, two-thirds of complaints were mild (67.4%, 95% CI 63.2–71.6) with the most common complaint being pain at the injection site (86.5%). Paracetamol or its combination with NSAIDs were used in the majority of cases (95.2%). After the second dose, only 31.2% (95% CI 27.2–35.2) reported adverse events, the overwhelming majority of which were mild (95.7%) and required a lower frequency of medication (7.5% vs. 26.0%). Adverse event following immunization were significantly associated with being 18–30 years old (χ2 = 16.9, df = 3, p < 0.001) and female gender (χ2 = 5.2, df = 1, p < 0.05). Prior to the first dose, 86.0% of participants (95% CI 83.3–88.8%) perceived the vaccine to be safe, and 96.0% recommended the vaccine post-vaccination, while 96.8% were interested in receiving the second dose. AEFI severity was negatively associated with vaccine recommendation to the peers (odds-ratio 0.062, p < 0.05) following the first dose, whereas, the optimistic pre-vaccination perception was associated with positive vaccine recommendation post-vaccination (odds-ratio 28.658, p < 0.01). Conclusions Overall, vaccination-associated events were mild and majority were managed with paracetamol or its combination. Effective counselling about adverse events before vaccination should be prioritized to reduce hesitation and fear. Supplementary Information The online version contains supplementary material available at 10.1186/s12879-022-07406-2.
Collapse
Affiliation(s)
- Kapil Madi Poudel
- Institute of Medicine, Tribhuvan University, Maharajgunj, Kathmandu, 44600, Nepal.,Dhankuta Institute of Health Science, Dhankuta, 56800, Nepal
| | - Neha Shah
- Dhankuta Institute of Health Science, Dhankuta, 56800, Nepal.,BP Koirala Institute of Health Sciences, Dharan, 56700, Nepal
| | - Manab Prakash
- Central Department of Economics, Tribhuvan University, Kirtipur, 44600, Nepal
| | | | - Sunita Bhandari
- BP Koirala Institute of Health Sciences, Dharan, 56700, Nepal
| | - Tika Ram Poudel
- GoldenGate International College, Tribhuvan University, Kathmandu, 44600, Nepal.
| |
Collapse
|
28
|
Joshi RK, Muralidharan C, Ahuja A, Mukherjee R, Chaurasia S, Manjaly L, Divyanshi, Sahoo A, Gosavi J, Thomas A. Vaccine effectiveness to protect against moderate or severe disease in COVID cases: A prospective cohort study. Med J Armed Forces India 2022; 79:S0377-1237(22)00016-8. [PMID: 35400799 PMCID: PMC8979476 DOI: 10.1016/j.mjafi.2022.02.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Accepted: 02/07/2022] [Indexed: 12/20/2022] Open
Abstract
Background This study was carried out to evaluate the effectiveness of partial and full vaccination with ChAdOx1 nCoV-19 (COVISHIELD) to prevent the development of moderate or severe illness among COVID-positive cases. Methods This prospective cohort study was conducted among Armed Forces personnel deployed in Northern India who were found COVID positive during the study period between January and June 2021. Information about the vaccination status, age and comorbidities was collected at the time of diagnosis. Classification of COVID cases as moderate or severe was performed as per criteria given by the Government of India. Individuals were considered partially vaccinated three weeks after one dose and fully vaccinated two weeks after the second dose. Risk ratio and vaccine effectiveness (VE) to prevent moderate or severe disease among COVID cases were calculated. Results A total of 2005 COVID-19 patients were included in our study. Partial vaccination and full vaccination with ChAdOx1 nCoV-19 offered 13% (95% credible interval (CI): -56.8%, 52.8%) and 66.6% (95% CI: 34.9%, 84.6%) protection against progression to moderate/severe illness among COVID-positive individuals. The risk of moderate-severe disease among COVID-positive cases occurring 4-11 weeks after the first dose was also lesser among those who had taken the second dose of vaccine than individuals who have been vaccinated with only one dose. Conclusion Interval between the first and second doses of ChAdOx1 nCoV-19 vaccine should be reduced to 4-6 weeks, as partial vaccination offers lower protection against the development of moderate-severe illness after COVID infection.
Collapse
Affiliation(s)
- Rajneesh K. Joshi
- Col AFMS (MR), O/o DGAFMS, A Block, MoD Offices Complex, Africa Avenue, New Delhi, India
| | - C.G. Muralidharan
- ADGMS (Army), O/o DGMS (Army), Defence Office Complex, KG Marg, New Delhi, India
| | - Ankur Ahuja
- Senior Registrar, 92 Base Hospital, C/o 56 APO, India
| | | | | | - Linto Manjaly
- Medical Officer, 4015 Field Hospital, C/o 56 APO, India
| | - Divyanshi
- Medical Officer, 92 Base Hospital, C/o 56 APO, India
| | - A.K. Sahoo
- DADH, HQ 19 Inf Div (Med), C/o 56 APO, India
| | | | - Alok Thomas
- Medical Officer, 439 Field Hospital, C/o 56 APO, India
| |
Collapse
|
29
|
Medigeshi GR, Batra G, Murugesan DR, Thiruvengadam R, Chattopadhyay S, Das B, Gosain M, Ayushi, Singh J, Anbalagan A, Shaman H, Pargai K, Mehdi F, Das SJ, Kahlon N, Singh S, Kshetrapal P, Wadhwa N, Pandey AK, Bhatnagar S, Garg PK. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months. EBioMedicine 2022; 78:103938. [PMID: 35305396 PMCID: PMC8923830 DOI: 10.1016/j.ebiom.2022.103938] [Citation(s) in RCA: 33] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 02/23/2022] [Accepted: 03/01/2022] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Rapid spread of the omicron SARS-CoV-2 variant despite extensive vaccination suggests immune escape. The neutralising ability of different vaccines alone or with natural SARS-CoV-2 infection against omicron is not well-known. METHODS In this cross-sectional study, we tested the ability of vaccine and natural infection induced antibodies to neutralise omicron variant in a live virus neutralisation assay in four groups of individuals: (i) ChAdOx1 nCoV-19 vaccination, (ii) ChAdOx1 nCoV-19 vaccination plus prior SARS-CoV-2 infection, (iii) vaccination with inactivated virus vaccine (BBV152), and (iv) BBV152 vaccination plus prior SARS-CoV-2 infection. Primary outcome was fold-change in virus neutralisation titre against omicron compared with ancestral virus. FINDINGS We included 80 subjects. The geometric mean titre (GMT) of the 50% focus reduction neutralisation test (FRNT50) was 380·4 (95% CI: 221·1, 654·7) against the ancestral virus with BBV152 vaccination and 379·3 (95% CI: 185·6, 775·2) with ChAdOx1 nCov-19 vaccination alone. GMT for vaccination plus infection groups were 806·1 (95% CI: 478·5, 1357·8) and 1526·2 (95% CI: 853·2, 2730·0), respectively. Against omicron variant, only 5 out of 20 in both BBV152 and ChAdOx1 nCoV-19 vaccine only groups, 6 out of 20 in BBV152 plus prior SARS-CoV-2 infection group, and 9 out of 20 in ChAdOx1 nCoV-19 plus prior SARS-CoV-2 infection group exhibited neutralisation titres above the lower limit of quantification (1:20) suggesting better neutralisation with prior infection. A reduction of 26·6 and 25·7 fold in FRNT50 titres against Omicron compared to ancestral SARS-CoV-2 strain was observed for individuals without prior SARS-CoV-2 infection vaccinated with BBV152 and ChAdOx1 nCoV-19, respectively. The corresponding reduction was 57·1 and 58·1 fold, respectively, for vaccinated individuals with prior infection. The 50% neutralisation titre against omicron demonstrated moderate correlation with serum anti-RBD IgG levels [Spearman r: 0·58 (0·41, 0·71)]. INTERPRETATION Significant reduction in the neutralising ability of both vaccine-induced and vaccine plus infection-induced antibodies was observed for omicron variant which might explain immune escape. FUNDING Department of Biotechnology, India; Bill & Melinda Gates Foundation, USA.
Collapse
Affiliation(s)
| | - Gaurav Batra
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | | | | | - Souvick Chattopadhyay
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Bhabatosh Das
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Mudita Gosain
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Ayushi
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Janmejay Singh
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Anantharaj Anbalagan
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Heena Shaman
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Kamal Pargai
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Farha Mehdi
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Soon Jyoti Das
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Namrata Kahlon
- ESIC Medical College and Hospital, Faridabad, Haryana, India
| | - Savita Singh
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Pallavi Kshetrapal
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Nitya Wadhwa
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Anil K Pandey
- ESIC Medical College and Hospital, Faridabad, Haryana, India
| | - Shinjini Bhatnagar
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India
| | - Pramod Kumar Garg
- Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
| |
Collapse
|
30
|
Juyal D, Pal S, Thaledi S, Pandey HC. COVID-19: The vaccination drive in India and the Peltzman effect. J Family Med Prim Care 2022; 10:3945-3947. [PMID: 35136749 PMCID: PMC8797072 DOI: 10.4103/jfmpc.jfmpc_739_21] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Revised: 07/04/2021] [Accepted: 07/13/2021] [Indexed: 11/12/2022] Open
Abstract
The ongoing COVID-19 vaccine drives across the world, including India, may have caused people to adopt risky behavior such as decreased or non-adherence to COVID-appropriate social behavior. Such phenomenon in which people are more likely to engage in risky behavior when security measures have been mandated is termed as the “Peltzman Effect” and apart from the emergence of various variants, it may have contributed to the recent upsurge in the number of new COVID-19 cases across the world, including in India. To make the worldwide COVID-19 vaccine drive successful, it is important to acknowledge, understand and minimize the potential harms from Peltzman Effect.
Collapse
Affiliation(s)
- Deepak Juyal
- Department of Microbiology, Government Doon Medical College, Dehrakhas, Patel Nagar, Dehradun, Uttarakhand, India.,Department of Microbiology, Viral Research and Diagnostic Laboratories, Government Doon Medical College, Dehrakhas, Patel Nagar, Dehradun, Uttarakhand, India
| | - Shekhar Pal
- Department of Microbiology, Government Doon Medical College, Dehrakhas, Patel Nagar, Dehradun, Uttarakhand, India.,Department of Microbiology, Viral Research and Diagnostic Laboratories, Government Doon Medical College, Dehrakhas, Patel Nagar, Dehradun, Uttarakhand, India
| | - Shweta Thaledi
- Department of Microbiology, Viral Research and Diagnostic Laboratories, Government Doon Medical College, Dehrakhas, Patel Nagar, Dehradun, Uttarakhand, India
| | - Hem Chandra Pandey
- Department of Microbiology, Hemwati Nandan Bahuguna Uttarakhand Medical Education University, Dehradun, Uttarakhand, India
| |
Collapse
|
31
|
Singh AK, Phatak SR, Singh R, Bhattacharjee K, Singh NK, Gupta A, Sharma A. Humoral antibody kinetics with ChAdOx1-nCOV ( Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study. Diabetes Metab Syndr 2022; 16:102424. [PMID: 35150961 PMCID: PMC8816907 DOI: 10.1016/j.dsx.2022.102424] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 02/02/2022] [Accepted: 02/03/2022] [Indexed: 02/05/2023]
Abstract
BACKGROUND AND AIMS There is limited data available on longitudinal humoral antibody dynamics following two doses of ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine against SARS-CoV-2 among Indians. METHODS We conducted a 6-month longitudinal study in vaccinated healthcare workers by serially measuring quantitative anti-spike antibody at 3-weeks, 3-months and 6-months after the completion of second dose. Geometric mean titer (GMT) and linear mixed models were used to assess the dynamics of antibody levels at 6 months. RESULTS Of the 481 participants, GMT of anti-spike antibody decreased by 56% at 6-months regardless of age, gender, blood group, body-mass index and comorbidities in 360 SARS-CoV-2 naive individuals but significantly more in hypertensives. Participants with past infection had significantly higher GMT at all time points compared to the naive individuals. Among SARS-CoV-2 naive cohorts, a significantly higher GMT was noted amongst the Covishield recipients at all time points, but there was a 44% decline in GMT at 6-month compared to the peak titer period. Decline in GMT was insignificant (8%) in Covaxin recipients at 6-month despite a lower GMT at all time points vs. Covishield. There was 5.6-fold decrease in seropositivity rate at 6-month with both vaccines. Participants with type 2 diabetes mellitus have a lower seropositivity rate at all the time points. Seropositivity rate was significantly higher with Covishield vs. Covaxin at all time points except at 6-month where Covaxin recipients had a higher seropositivity rate but no difference noted in propensity-matched analysis. CONCLUSIONS There is waning humoral antibody response following two doses of either vaccine at six months. Covishield recipients had a higher anti-spike antibody GMT compared with Covaxin at all-time points, however a significant decline in antibody titers was seen with Covishield but not with Covaxin at 6-months.
Collapse
Affiliation(s)
- Awadhesh Kumar Singh
- Consultant Endocrinologist, G. D Hospital & Diabetes Institute, Kolkata, West Bengal, India.
| | | | - Ritu Singh
- Consultant Gynecologist, G. D Hospital & Diabetes Institute, Kolkata, West Bengal, India
| | | | | | - Arvind Gupta
- Department of Diabetes, Obesity and Metabolic Disorders, Rajasthan Hospital, Jaipur, Rajasthan, India
| | - Arvind Sharma
- Associate Professor, Dept. of Community Medicine, Mahatma Gandhi Medical College & Hospital, Jaipur, Rajasthan, India
| |
Collapse
|
32
|
Deb T, Garg R, Kaur M, Beniwal A, Gupta V. ADR Profile of the Covishield Vaccine among Healthcare Workers in a Tertiary Care Teaching Hospital in India. Curr Drug Saf 2022; 17:344-349. [PMID: 35049437 DOI: 10.2174/1574886317666220113101815] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 10/31/2021] [Accepted: 11/06/2021] [Indexed: 11/22/2022]
Abstract
BACKGROUND Coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/2019-nCoV). Though many classes of drugs have been advocated/ used for the treatment of this disease, vaccines are being targeted for the ultimate prevention of this deadly disease. Indian Government has approved Covishield (ChAdOx1 nCoV19 Corona Virus Vaccine-Recombinant) for restricted use in emergency circumstances Objective. This study is aimed at evaluating the safety profile of the Covishield vaccine among healthcare workers in a tertiary care hospital. METHODS All Adverse Drug Reactions (ADRs) reported to ADR monitoring centre by healthcare workers who received the Covishield vaccine during the study period of 3 months were analysed on various parameters and the assessment was done using WHO-UMC scale. RESULTS During the study period, total of 1216 beneficiaries were vaccinated with 1st dose of Covishield and out of these, 727 beneficiaries also received 2nd dose of the vaccine. Out of total 1216 beneficiaries vaccinated, 69 ADRs were reported in 24 healthcare workers. The most common ADR reported was fever (25%), followed by myalgia (19%). No death or any serious anaphylactic reaction was observed. None of the healthcare workers experienced any adverse event during the observation period of 30 minutes. Serious reactions were reported in 4 healthcare workers as per the Pharmacovigilance Programme of India (PvPI) criteria of Serious AEFI. 92% of healthcare workers recovered from ADRs during the study period. 84% of ADRs were classified as probable as per the WHO-UMC scale. CONCLUSION As per the Government of India directives all the healthcare workers in the institute were encouraged to take both doses of the Covishield vaccine. The beneficiaries were kept under observation for 30 minutes and followed for any adverse drug reaction following vaccination. The vaccine was found to be safe with a very low incidence of ADRs.
Collapse
Affiliation(s)
- Tirthankar Deb
- Adverse Drug Reaction Monitoring Centre, Department of Pharmacology, Kalpana Chawla Govt Medical College, Karnal, Haryana, India
| | - Rajesh Garg
- Department of Community Medicine, Kalpana Chawla Govt. Medical College, Karnal, Haryana, India
| | - Manmeet Kaur
- Adverse Drug Reaction Monitoring Centre, Department of Pharmacology, Kalpana Chawla Govt Medical College, Karnal, Haryana, India
| | - Ankita Beniwal
- Adverse Drug Reaction Monitoring Centre, Department of Pharmacology, Kalpana Chawla Govt Medical College, Karnal, Haryana, India
| | - Varsha Gupta
- Department of Community Medicine, Kalpana Chawla Govt. Medical College, Karnal, Haryana, India
| |
Collapse
|
33
|
Mahadevaiah A, Doddamadaiah C, K S S, Cholenahalli Nanjappa M. Study of immunogenicity, safety and efficacy of covishield vaccine among health care workers in a tertiary cardiac care centre. Indian J Med Microbiol 2022; 40:200-203. [PMID: 35422343 PMCID: PMC9000002 DOI: 10.1016/j.ijmmb.2022.03.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2021] [Revised: 03/07/2022] [Accepted: 03/09/2022] [Indexed: 02/08/2023]
Abstract
PURPOSE The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, and immunogenicity of Covishield vaccine among Health care workers (HCWs) in a tertiary cardiac care centre. METHODS It's a prospective analytical study, conducted at Sri Jayadeva Institute of cardiovascular science and research centre, Mysore, between January 2021 to May 2021. Pre and Post vaccination SARS CoV2 IgG antibodies were assessed among 122 HCWs. Interval between two doses in this study were 4 and 6 weeks. Adverse events following immunisation b(AEFI) and efficacy were assessed and followed up for two month post vaccination. RESULTS Post vaccination seropositivity was 69.67% in overall study participants. Seropositivity and P/N ratio median value in uninfected and infected group were 60.43% (n = 55),3.47 (IQR: 2.56-5.22) and 96.77% (n = 30),9.49 (IQR: 7.57-12.30) respectively (P < 0.001). Seropositivity and P/N ratio after 4 and 6 weeks were 48.3% (n = 60), 2.95 (IQR: 1.91-4.24), and 83.8% (n = 31), 4.88, (IQR: 3.39-6.43) respectively (P < 0.001). AEFI after first and second dose was 72.9% and 27.8% (p < 0.05) respectively. The most common symptoms after both doses of vaccination were local pain (73% & 88.2%), followed by fever (38.2% & 26.5%). The average duration of symptoms in both doses was 1.75 days. Of 122 participants only 10 (8.19%) had breakthrough infection after two doses of vaccination with mild severity. CONCLUSION Covishield vaccine has showed seropositivity of 69.67%.It has acceptable level of safety profile. Seropositivity and P/N ratio has increased with increase in interval between two doses. Though it has not prevented breakthrough infection it has certainly reduced the severity of infection.
Collapse
|
34
|
Kant R, Dwivedi G, Zaman K, Sahay RR, Sapkal G, Kaushal H, Nyayanit DA, Yadav PD, Deshpande G, Singh R, Chaowdhary S, Gupta N, Kumar S, Abraham P, Panda S, Bhargava B. Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin. J Travel Med 2021; 28:6397775. [PMID: 34652440 PMCID: PMC8524638 DOI: 10.1093/jtm/taab166] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/2021] [Revised: 10/12/2021] [Accepted: 10/12/2021] [Indexed: 11/21/2022]
Abstract
The evidence for effectiveness of heterologous priming of COVID-19 vaccine is very limited. Here, we studied eighteen participants who received heterologous vaccination regimen of AstraZeneca’s ChAdOx1-nCov-19 followed by inactivated whole virion BBV152. Heterologous group participant doesn’t report any adverse event following immunization and demonstrated high humoral and neutralizing antibody response.
Collapse
Affiliation(s)
- Rajni Kant
- Indian Council of Medical Research-Regional Medical Research Centre (RMRC), Gorakhpur, Uttar Pradesh, 273013, India
| | - Gaurav Dwivedi
- Indian Council of Medical Research-Regional Medical Research Centre (RMRC), Gorakhpur, Uttar Pradesh, 273013, India
| | - Kamran Zaman
- Indian Council of Medical Research-Regional Medical Research Centre (RMRC), Gorakhpur, Uttar Pradesh, 273013, India
| | - Rima R Sahay
- Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India
| | - Gajanan Sapkal
- Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India
| | - Himanshu Kaushal
- Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India
| | - Dimpal A Nyayanit
- Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India
| | - Pragya D Yadav
- Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India
| | - Gururaj Deshpande
- Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India
| | - Rajeev Singh
- Indian Council of Medical Research-Regional Medical Research Centre (RMRC), Gorakhpur, Uttar Pradesh, 273013, India
| | - Sandeep Chaowdhary
- Chief Medical Officer, Community Health Centre, Siddarthnagar, Uttar Pradesh, 272207, India
| | - Nivedita Gupta
- Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi, 110029, India
| | - Sanjay Kumar
- Command Hospital (Southern Command), Armed Forces Medical College, Pune, Maharashtra, 411040, India
| | - Priya Abraham
- Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India
| | - Samiran Panda
- Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi, 110029, India
| | - Balram Bhargava
- Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi, 110029, India
| |
Collapse
|
35
|
Abstract
Coronavirus disease 2019 (COVID-19) is known to cause thromboembolic episodes apart from acute respiratory distress syndrome (ARDS). With large vaccine drives all across the world, there are a few case reports on post-vaccine thrombotic events seen with the AZD1222, ChAdO × 1 vaccine. Here, we present two cases of central retinal vein occlusion presenting immediately after receiving the second dose of the Covishield vaccine. Although the causal relationship cannot be drawn, the ophthalmologist should be aware of this adverse reaction.
Collapse
Affiliation(s)
- Nikita J Sonawane
- Vitreo-Retina Services, Aravind Eye Hospital, Thavalakuppam, Pondicherry, India
| | - Divya Yadav
- Vitreo-Retina Services, Aravind Eye Hospital, Thavalakuppam, Pondicherry, India
| | - Annaji Rao Kota
- Vitreo-Retina Services, Aravind Eye Hospital, Thavalakuppam, Pondicherry, India
| | - Harsh Vardhan Singh
- Vitreo-Retina Services, Aravind Eye Hospital, Thavalakuppam, Pondicherry, India
| |
Collapse
|
36
|
Abstract
BACKGROUND Reports of transmission of COVID-19 from a vaccinated healthcare worker (HCW) to vaccinated co-workers are sparse. METHODS Index case (IC): After the second dose of the ChAdOx1 nCoV-19 vaccine, a HCW - our IC was diagnosed of COVID-19 by a rapid antigen test (RAT). A reverse transcription-polymerase chain reaction (RT-PCR) test done on the same day showed a cycle threshold (Ct) value of 10.02 (a very high viral load). Contact tracing and findings: The authors traced IC's contacts and seven contacts were identified. Four of those (P 1-4) were tested positive for COVID-19 on day12 after the contact. P1-2 were vaccinated and had slept near the IC in an enclosed 5.5 × 2.7 × 2.4 m room without air change and without masks, while IC was symptomatic. P3 and P4 came in immediately after IC left that room and slept there without masks. We did not find any other exposures of P1-4 within the 14 days (d) before they tested positive. CONCLUSIONS P1 and P2 are COVID-19 vaccine breakthrough infections. P3 and P4 contracting infection in the physical absence of IC indicates probable aerosol transmission of COVID-19. The factors that led to this episode, namely, unfamiliarity of breakthrough COVID-19 infections, ignoring the risk of contracting COVID-19 from vaccinated co-workers, hesitancy in seeking medical care soon after the onset of symptoms, poorly ventilated and cramped resting rooms for HCW exists worldwide. This episode reiterates the importance of adhering to basic COVID-19 preventive measures even after vaccination.
Collapse
Affiliation(s)
- N D B Ehelepola
- Teaching (General) Hospital-Peradeniya, Peradeniya, Sri Lanka
| | | |
Collapse
|
37
|
Potdar M, Potdar S, Potdar M. A study of gender disparities towards COVID-19 vaccination drive in Maharashtra State, India. Diabetes Metab Syndr 2021; 15:102297. [PMID: 34571358 PMCID: PMC8459578 DOI: 10.1016/j.dsx.2021.102297] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 09/03/2021] [Accepted: 09/17/2021] [Indexed: 11/18/2022]
Abstract
BACKGROUND AND AIMS India officially launched the world's biggest COVID-19 vaccination drive on January 16, 2021, operating 3006 vaccination sites at the beginning. At present 21872 sites conducting vaccination as on August 24, 2021. The process of vaccination is not yet mandatory in India. Vaccination is conducted free of cost at 20242 Government sites and paid at 1630 private sites. This study involves Hypothesis Testing for analyzing the gender disparities towards COVID-19 vaccination. METHODS For this study, we have used Maharashtra States district wise COVID-19 vaccination data. Using Hypothesis Testing method Pearson's Chi-square test for independence compares two variables gender disparities and vaccination in a contingency table to see if they are related. To test the Effect size of gender disparities is small, medium or large Cohen Cramer's rule is used. RESULTS Our result shows that, just 84 women were vaccinated for every 100 men in Maharashtra State, India. This ratio is even lower than India's gender ratio i.e. 90:100. Men were more aware and ahead of women in COVID-19 Vaccination Drive. Effect size shows that size of gender disparities is small. CONCLUSION As per the result it is seen that COVID-19 Vaccination awareness is slightly less amongst the women in Maharashtra, India. To improve this statistics of COVID-19 Vaccination, Authorities should start the awareness campaign amongst the citizen towards the importance of vaccination.
Collapse
|
38
|
Kripalani Y, Lakkappan V, Parulekar L, Shaikh A, Singh R, Vyas P. A Rare Case of Guillain-Barré Syndrome following COVID-19 Vaccination. Eur J Case Rep Intern Med 2021; 8:002707. [PMID: 34671572 DOI: 10.12890/2021_002797] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Accepted: 08/13/2021] [Indexed: 01/28/2023] Open
Abstract
Various vaccines against COVID-19 have been developed since SARS-CoV-2 emerged at the end of 2019. Their emergency administration in healthcare settings has been accompanied by numerous adverse effects. A case of Guillain-Barré syndrome following vaccination with Covishield is presented here to highlight this possible adverse condition. LEARNING POINTS Guillain-Barré Syndrome (GBS) is a very rare complication after vaccination against SARS-CoV-2.The key concepts related to the understanding, management and outcomes of patients with GBS are discussed.
Collapse
Affiliation(s)
- Yash Kripalani
- Department of Critical Care Medicine, Holy Family Hospital, Bandra, Mumbai, India
| | - Vidyadhara Lakkappan
- Department of Critical Care Medicine, Holy Family Hospital, Bandra, Mumbai, India
| | - Lipeeka Parulekar
- Department of General Internal Medicine, Holy Family Hospital, Bandra, Mumbai, India
| | - Anjum Shaikh
- Department of Critical Care Medicine, Holy Family Hospital, Bandra, Mumbai, India
| | - Rakesh Singh
- Department of Neurology, Holy Family Hospital, Bandra, Mumbai, India
| | - Pradeep Vyas
- Department of Critical Care Medicine, Holy Family Hospital, Bandra, Mumbai, India
| |
Collapse
|
39
|
Jahan N, Rahman FI, Saha P, Ether SA, Roknuzzaman ASM, Sarker R, Kalam KT, Haq K, Nyeen J, Himi HZ, Hossain MN, Chowdhury MH, Uddin MM, Alam NH. Side Effects Following Administration of the First Dose of Oxford-AstraZeneca's Covishield Vaccine in Bangladesh: A Cross-Sectional Study. Infect Dis Rep 2021; 13:888-901. [PMID: 34698203 PMCID: PMC8544399 DOI: 10.3390/idr13040080] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2021] [Revised: 09/27/2021] [Accepted: 10/06/2021] [Indexed: 12/11/2022] Open
Abstract
In response to the raging COVID-19 pandemic, Bangladesh started its vaccine administration in early 2021; however, due to the rapid development and launch of the vaccines in the market, many people had concerns regarding the safety of these vaccines. The purpose of this study was to evaluate the side effects that were experienced by the Bangladeshi residents after receiving the first dose of the Oxford-AstraZeneca’s Covishield vaccine (ChAdOx1nCoV-19). The study was conducted using both online and printed questionnaires and the data were analysed using SPSS. The results included the responses of 474 vaccine recipients from March–April 2021. Pain at the site of injection, fever, myalgia, fatigue and headache were the most commonly reported symptoms, and the overall side effects were found to be significantly more prevalent in the younger population (p ≤ 0.05). These findings were consistent with the results indicated by the clinical trial of ChAdOx1nCoV-19. Logistic regression analysis further revealed that compared to people aged 70 years or above, the incidence of reported side effects was significantly higher in people aged 18–30 years (odds ratio (OR) = 8.56), 31–40 years, (OR = 5.05), 41–50 years (OR = 4.08), 51–60 years (OR = 3.77) and 61–70 years (OR = 3.67). In addition, a significantly higher percentage of female participants suffered from post-vaccination side effects compared to males (OR = 1.51). It was concluded that the Covishield vaccine was well-tolerated among people of different age groups. Nevertheless, further long-term follow-up study with a larger sample size is warranted to establish the long-term safety of the COVID-19 vaccine.
Collapse
Affiliation(s)
- Nishat Jahan
- Department of Pharmacy, University of Asia Pacific, Green Road, Dhaka 1205, Bangladesh; (A.R.); (R.S.); (K.T.K.); (K.H.); (J.N.); (H.Z.H.); (M.N.H.); (M.H.C.)
- Correspondence:
| | - Fahad Imtiaz Rahman
- Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh; (F.I.R.); (P.S.)
| | - Poushali Saha
- Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh; (F.I.R.); (P.S.)
| | - Sadia Afruz Ether
- Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, Bangladesh;
| | - ASM Roknuzzaman
- Department of Pharmacy, University of Asia Pacific, Green Road, Dhaka 1205, Bangladesh; (A.R.); (R.S.); (K.T.K.); (K.H.); (J.N.); (H.Z.H.); (M.N.H.); (M.H.C.)
| | - Rapty Sarker
- Department of Pharmacy, University of Asia Pacific, Green Road, Dhaka 1205, Bangladesh; (A.R.); (R.S.); (K.T.K.); (K.H.); (J.N.); (H.Z.H.); (M.N.H.); (M.H.C.)
| | - Khondoker Tashya Kalam
- Department of Pharmacy, University of Asia Pacific, Green Road, Dhaka 1205, Bangladesh; (A.R.); (R.S.); (K.T.K.); (K.H.); (J.N.); (H.Z.H.); (M.N.H.); (M.H.C.)
| | - Kashfa Haq
- Department of Pharmacy, University of Asia Pacific, Green Road, Dhaka 1205, Bangladesh; (A.R.); (R.S.); (K.T.K.); (K.H.); (J.N.); (H.Z.H.); (M.N.H.); (M.H.C.)
| | - Julkar Nyeen
- Department of Pharmacy, University of Asia Pacific, Green Road, Dhaka 1205, Bangladesh; (A.R.); (R.S.); (K.T.K.); (K.H.); (J.N.); (H.Z.H.); (M.N.H.); (M.H.C.)
| | - Humayra Zaman Himi
- Department of Pharmacy, University of Asia Pacific, Green Road, Dhaka 1205, Bangladesh; (A.R.); (R.S.); (K.T.K.); (K.H.); (J.N.); (H.Z.H.); (M.N.H.); (M.H.C.)
| | - Md. Nazmul Hossain
- Department of Pharmacy, University of Asia Pacific, Green Road, Dhaka 1205, Bangladesh; (A.R.); (R.S.); (K.T.K.); (K.H.); (J.N.); (H.Z.H.); (M.N.H.); (M.H.C.)
| | - Mahtab Hossain Chowdhury
- Department of Pharmacy, University of Asia Pacific, Green Road, Dhaka 1205, Bangladesh; (A.R.); (R.S.); (K.T.K.); (K.H.); (J.N.); (H.Z.H.); (M.N.H.); (M.H.C.)
| | - Mostafa Moin Uddin
- Office of the Director General, Directorate General of Health Services (DGHS), Mohakhali, Dhaka 1212, Bangladesh;
| | - Nur Haque Alam
- Nutrition and Clinical Services Division (NCSD), International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Mohakhali, Dhaka 1000, Bangladesh;
| |
Collapse
|
40
|
Mishra K, Barki S, Pattanayak S, Shyam M, Sreen A, Kumar S, Kotwal J. COVID-19 Vaccine-Induced Thrombosis and Thrombocytopenia: First Confirmed Case from India. Indian J Hematol Blood Transfus 2021;:1-3. [PMID: 34608364 DOI: 10.1007/s12288-021-01492-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Accepted: 09/18/2021] [Indexed: 11/06/2022] Open
|
41
|
Abstract
The coronavirus disease 2019 (COVID-19) pandemic continues to bring in its wake not only morbidity and mortality but also an unprecedented challenge to public health, food systems, human dignity, and work across the world. The availability and possible delivery of a safe and effective vaccine to populations across the world are not only being seen as a hope to surmount these challenges but also as a show of human resilience in the face of adversity. Nations need to galvanize their resources and make the availability of vaccines universal, without which the real benefits of its development cannot be realized. Despite its large domestic needs, our country is being looked upon with both hope and expectation to deliver at this crucial juncture in the evolution of human civilization, and India is more than willing to do its part.
Collapse
Affiliation(s)
- Sunil Kumar Raina
- Community Medicine, Dr. RP Government Medical College, Tanda, Himachal Pradesh, India
| | - Raman Kumar
- President, Academy of Family Physicians of India, New Delhi, India
| |
Collapse
|
42
|
Bhattacharya A, Ranjan P, Ghosh T, Agarwal H, Seth S, Maher GT, Upadhyay AD, Kumar A, Baitha U, Gupta G, Prakash B, Dwivedi SN, Wig N. Evaluation of the dose-effect association between the number of doses and duration since the last dose of COVID-19 vaccine, and its efficacy in preventing the disease and reducing disease severity: A single centre, cross-sectional analytical study from India. Diabetes Metab Syndr 2021; 15:102238. [PMID: 34364299 PMCID: PMC8321688 DOI: 10.1016/j.dsx.2021.102238] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Revised: 07/26/2021] [Accepted: 07/27/2021] [Indexed: 02/03/2023]
Abstract
AIMS To evaluate the dose-effect association between COVID-19 vaccination and probability of turning RT-PCR positive and to assess the correlation between disease severity and vaccination status. METHODS A single centre cross-sectional study was conducted amongst 583 individuals presenting to COVID-19 testing clinic and 55 hospitalized COVID-19 patients. Vaccination status was assessed by the number of doses and duration since the last dose. Disease severity was evaluated by the requirement of hospitalisation and ICU admission/death. The association between the vaccination status and development of disease and its severity were statistically analyzed. RESULTS The mean age of the population was 36.6 years and 82.6% had no comorbidities. The odds of turning RT-PCR positive was 0.17(95% CI: 0.11-0.27) among the clinical suspects who had taken both doses of the vaccine at least 14 days before (fully vaccinated). The odds of hospitalisation was 0.12(95% CI: 0.03-0.45) and ICU admission/death was 0.07(95% CI: 0.01-0.36) among fully vaccinated individuals. The protective role of vaccination was observed to start 14 days after receiving the first dose. CONCLUSIONS COVID-19 vaccination provides dose-dependent protection against the development of the disease. It also lowers the risk of hospitalisation and ICU admission/death in RT-PCR positive patients in a dose-dependent manner.
Collapse
Affiliation(s)
| | - Piyush Ranjan
- Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
| | - Tamoghna Ghosh
- All India Institute of Medical Sciences, New Delhi, India
| | - Harsh Agarwal
- All India Institute of Medical Sciences, New Delhi, India
| | - Sukriti Seth
- Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
| | | | - Ashish Datt Upadhyay
- Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India
| | - Arvind Kumar
- Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
| | - Upendra Baitha
- Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
| | - Gaurav Gupta
- Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
| | - Bindu Prakash
- Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
| | - Sada Nand Dwivedi
- Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India
| | - Naveet Wig
- Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
| |
Collapse
|
43
|
Thirumalairaj R, Parikh PM, Agarwal A, Singh R, Krishnamurthy A, Desai SS, Maheshwari A, Mehta P, Ghafur A, Somashekhar SP, Iqbal A, Savant DN, Hussain SMA, Bhatt A, Wangdi T, Bajpai J, Ranade AA, Babu KG, Bapna A, Biswas G, Malhotra H, Krishna MV, Baral RP, Vashishtha R, Safi AJ, Agarwal S, Agarwal JP, Rathnam KK, Mohapatra PN, Kumar RV, Rajappa S, Limaye SA, Vora A, Reddy VAP, Parekh BB, Rath GK. South Asian Declaration-Consensus Guidelines for COVID-19 Vaccination in Cancer Patients. South Asian J Cancer 2021; 10:3-8. [PMID: 34430512 PMCID: PMC8378920 DOI: 10.1055/s-0041-1731909] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
We provide the South Asian Declaration, containing the consensus guidelines for coronavirus disease 2019 (COVID-19) vaccination in cancer patients.
Collapse
Affiliation(s)
- Raja Thirumalairaj
- Department of Medical Oncology, Apollo Cancer Center, Teynampet, Chennai, India
| | - Purvish M Parikh
- Department of Oncology, Integrated Academic Society of Clinical Oncology, Mumbai Oncocare Centers, Mumbai, Maharashtra, India
| | - Amit Agarwal
- Department of Medical Oncology, BLK Superspecilaity Hospital, Delhi, India
| | - Randeep Singh
- Department of Molecular Oncology Society, Narayana Health, Delhi, India
| | | | - Sharad S Desai
- Department of Surgical Oncology, Mahatma Gandhi Cancer Hospital, Miraj, Maharashtra, India
| | - Amita Maheshwari
- Divison of Gynecologic Oncology, Department of Surgical Oncology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Prashant Mehta
- Department of Medical Oncology/Hematoncology/BMT, Asian Institute of Medical Sciences, Faridabad, India
| | - Abdul Ghafur
- Department of Infectious Diseases, Apollo Cancer Institute, Chennai, India
| | - S P Somashekhar
- Department of Surgical Oncology, MHEPL, Manipal Comprehensive Cancer Center, Manipal Hospital, Bengaluru, India
| | - Ahamed Iqbal
- Oncology and Radiotherapy Department, Teaching Hospital, Batticaloa, Sri Lanka
| | | | - Syed Md Akram Hussain
- Department of Radiotherapy, Square Oncology and Radiotherapy Centre, Dhaka, Bangladesh
| | - Amit Bhatt
- Department of Medical Oncology, Avinash Cancer Clinic, Pune, India
| | - Tashi Wangdi
- Oncology Department, JDWNR Hospital and KGUMS, Thimphu, Bhutan
| | - Jyoti Bajpai
- Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India
| | | | - K Govind Babu
- Department of Medical and Pediatric Oncology, St. Johns Medical College and Hospital, HCG Hospitals, Bangalore, India
| | - Ajay Bapna
- Department of Medical Oncology, BMCHRC, Jaipur, Rajasthan, India
| | - Ghanshyam Biswas
- Department of Medical Oncology, Sparsh Hospital and Sum Hospital, Bhubaneswar, Odisha, India
| | - Hemant Malhotra
- Department of Medical Oncology, Sri Ram Cancer Center, Mahatma Gandhi Medical College Hospital, Jaipur, Rajasthan, India
| | - M Vamshi Krishna
- Department of Medical Oncology and Hematology, Institute of Oncology, AIG Hospitals, Gachibowli, Hyderabad, India
| | - Rajendra Prasad Baral
- Department of Medical Oncology, Norvic International Hospital and Om Hospital and Research Center, Kathmandu, Nepal
| | - Rajesh Vashishtha
- Department of Radiation Oncology, Max Super Speciality Hospital, Bathinda, Punjab, India
| | - Ahmad Javid Safi
- Afghanistan Cancer Foundation and Covid-19 Control Command Centre, Kabil, Afghanistan
| | - Sharmila Agarwal
- Department of Radiotherapy, Jaslok Hospital, Mumbai, Maharashtra, India
| | - J P Agarwal
- Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Krishna Kumar Rathnam
- Department of Medical Oncology, Meenakshi Mission Hospital and Research Centre, Madurai, India
| | - P N Mohapatra
- Department of Medical Oncology, Apollo Gleneagles Hospital, Kolkata, West Bengal, India
| | - Rajeev Vijay Kumar
- Department of Oncology, BGS Gleneagles Global Hospital, Bangalore, India
| | - Senthil Rajappa
- Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital and Research Center, Hyderabad, India
| | - Sewanti Atul Limaye
- Department of Oncology and Oncology Research, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India
| | - Amish Vora
- Department of Oncology, H.O.P.E. Oncology Cancer Clinic, PSRI Hospital, New Delhi, India
| | - Vijay A P Reddy
- Department of Radiation Oncology, Apollo Cancer Institute, Hyderabad, India
| | - Bhavesh B Parekh
- Department of Oncology, Shalby Cancer and Research Institute, Ahmedabad, Gujrat, India
| | - G K Rath
- National Cancer Center, Delhi, India
| |
Collapse
|
44
|
Mathivathanan K. Will COVID-19 vaccine equity be possible in India? Vaccine 2021; 39:4928-4929. [PMID: 34330556 PMCID: PMC8295011 DOI: 10.1016/j.vaccine.2021.07.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2021] [Revised: 07/17/2021] [Accepted: 07/19/2021] [Indexed: 11/24/2022]
Affiliation(s)
- Kanagavalli Mathivathanan
- Department of Obstetrics, Maharshi Menhi Homoeopathic Medical College & Hospital, Jeewach Nagar, Rojitpur, Katihar, Bihar 854105, India.
| |
Collapse
|
45
|
Rela M, Jothimani D, Vij M, Rajakumar A, Rammohan A. Auto-immune hepatitis following COVID vaccination. J Autoimmun 2021; 123:102688. [PMID: 34225251 DOI: 10.1016/j.jaut.2021.102688] [Citation(s) in RCA: 64] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2021] [Revised: 06/20/2021] [Accepted: 06/23/2021] [Indexed: 12/13/2022]
Abstract
Unprecedented loss of life due to the COVID pandemic has necessitated the development of several vaccines in record time. Most of these vaccines have received approval without being extensively whetted for their adverse effect and efficacy profiles. Most adverse effects have been mild, nonetheless, more serious thromboembolic events have also been reported. Autoimmune hepatitis (AIH) can occur in predisposed individuals where an immune mediated reaction against hepatocytes is triggered by environmental factors. Vaccines are a very rare cause of AIH. We report two such cases of AIH triggered by COVID (Covishield) vaccination. While one patient made an uneventful recovery, another succumbed to the liver disease. Ours is the first report of Covishield vaccination related AIH and second ever after any form of COVID vaccination. We hope that our report does not deter COVID vaccination drives. However, we also hope to raise awareness of its potential side effects and the increased role of pharmacovigilance in guiding treatment.
Collapse
Affiliation(s)
- Mohamed Rela
- The Institute of Liver Disease & Transplantation, Dr.Rela Institute & Medical Centre, Bharath Institute of Higher Education & Research, Chennai, India.
| | - Dinesh Jothimani
- The Institute of Liver Disease & Transplantation, Dr.Rela Institute & Medical Centre, Bharath Institute of Higher Education & Research, Chennai, India.
| | - Mukul Vij
- The Institute of Liver Disease & Transplantation, Dr.Rela Institute & Medical Centre, Bharath Institute of Higher Education & Research, Chennai, India.
| | - Akila Rajakumar
- The Institute of Liver Disease & Transplantation, Dr.Rela Institute & Medical Centre, Bharath Institute of Higher Education & Research, Chennai, India.
| | - Ashwin Rammohan
- The Institute of Liver Disease & Transplantation, Dr.Rela Institute & Medical Centre, Bharath Institute of Higher Education & Research, Chennai, India.
| |
Collapse
|
46
|
Abstract
The coronavirus disease 2019 (COVID-19) vaccine was launched in India on 16 January 2021, prioritising health care workers which included medical students. We aimed to assess vaccine hesitancy and factors related to it among medical students in India. An online questionnaire was filled by 1068 medical students across 22 states and union territories of India from 2 February to 7 March 2021. Vaccine hesitancy was found among 10.6%. Concern regarding vaccine safety and efficacy, lack of awareness regarding their eligibility for vaccination and lack of trust in government agencies predicted COVID-19 vaccine hesitancy among medical students. On the other hand, the presence of risk perception regarding themselves being affected with COVID-19 reduced vaccine hesitancy as well as hesitancy in participating in COVID-19 vaccine trials. Vaccine-hesitant students were more likely to derive information from social media and less likely from teachers at their medical colleges. Choosing between the two available vaccines (Covishield and Covaxin) was considered important by medical students both for themselves and for their future patients. Covishield was preferred to Covaxin by students. Majority of those willing to take the COVID-19 vaccine felt that it was important for them to resume their clinical posting, face-to-face classes and get their personal life back on track. Around three-fourths medical students viewed that COVID-19 vaccine should be made mandatory for both health care workers and international travellers. Prior adult vaccination did not have an effect on COVID-19 vaccine hesitancy. Targeted awareness campaigns, regulatory oversight of vaccine trials and public release of safety and efficacy data and trust building activities could further reduce COVID-19 vaccine hesitancy among medical students.
Collapse
|